

The relationship between controllability, optimal testing resource allocation, and incubation-latent period mismatch as revealed by COVID-19

Jeffery Demers^{1,2, *}, William F. Fagan², Sriya Potluri², and Justin M. Calabrese^{1,2,3}

¹Center for Advanced Systems Understanding (CASUS), Helmholtz-Zentrum Dresden-Rosendorf (HZDR), Görlitz, Germany

²Dept. of Biology, University of Maryland, College Park, MD, USA

³Dept. of Ecological Modelling, Helmholtz Centre for Environmental Research-UFZ, Leipzig, Germany

*Corresponding author; Email: jdemers@umd.edu

Abstract

The severe shortfall in testing supplies during the initial COVID-19 outbreak and ensuing struggle to manage the pandemic have affirmed the critical importance of optimal supply-constrained resource allocation strategies for controlling novel disease epidemics. To address the challenge of constrained resource optimization for managing diseases with complications like pre- and asymptomatic transmission, we develop an integro partial differential equation compartmental disease model which incorporates realistic latent, incubation, and infectious period distributions along with limited testing supplies for identifying and quarantining infected individuals. Our model overcomes the limitations of typical ordinary differential equation compartmental models by decoupling symptom status from model compartments to allow a more realistic representation of symptom onset and presymptomatic transmission. To analyze the influence of these realistic features on disease controllability, we find optimal strategies for reducing total infection sizes that allocate limited testing resources between ‘clinical’ testing, which targets symptomatic individuals, and ‘non-clinical’ testing, which targets non-symptomatic individuals. We apply our model not only to the original, delta, and omicron COVID-19 variants, but also to generically parameterized disease systems with varying mismatches between latent and incubation period distributions, which permit varying degrees of presymptomatic transmission or symptom onset before infectiousness. We find that factors that decrease controllability generally call for reduced levels of non-clinical testing in optimal strategies, while the relationship between incubation-latent mismatch, controllability, and optimal strategies is complicated. In particular, though greater degrees of presymptomatic transmission reduce disease controllability, they may increase or decrease the role of non-clinical testing in optimal strategies depending on other disease factors like transmissibility and latent period length. Importantly, our model allows a spectrum of diseases to be compared within a consistent framework such that lessons learned from COVID-19 can be transferred to resource constrained scenarios in future emerging epidemics and analyzed for optimality.

Keywords: Testing Quarantine Control, Optimal Resource Allocation, Presymptomatic Transmission, Latent Period, Incubation Period, Age of Infection

29 1 Introduction

30 Since its declaration as a global pandemic in March 2020 (1), COVID-19 has caused over 600
31 million cumulative infections and 6 million deaths (2). This loss of life and productivity together
32 with ubiquitous lockdowns and mobility restrictions have resulted in devastating socioeconomic
33 consequences worldwide (3, 4). The particularly severe costs of lockdowns underscore the need for
34 effective large scale test-trace-quarantine programs to combat emerging disease epidemics and save
35 lives while keeping society open and functioning. Unfortunately, for an epidemic caused by a novel
36 pathogen, testing supplies and health care infrastructure may be inadequate to meet demand as
37 health agencies struggle to implement new techniques and technologies at population-wide scales.
38 During the initial phases of the COVID-19 pandemic, for example, testing capacities fell well-short
39 of the levels required to monitor populations and test all suspected cases, while processing delays
40 limited the usefulness of the tests that were actually available (5, 6). Even now, 3 years after the
41 emergence of COVID-19, testing supplies have repeatedly struggled to meet the demand during
42 case surges associated with new COVID variants (6).

43 When COVID resources have fallen short of demand, experts and health agencies have rec-
44 ommended the prioritization of testing supplies to the most severely symptomatic and vulnerable
45 patients typically found in clinical health care settings, rather than to non-clinical cases associated
46 with mildly or asymptomatic individuals and population monitoring programs (6, 7, 8). This strat-
47 egy seeks to maximize the utility of the few resources available by limiting the amount ‘wasted’
48 on individuals who are not infected, but in the process excludes the possibility of slowing disease
49 spread by identifying and quarantining non-symptomatic infected individuals (9). Achieving an
50 ideal balance between clinical and non-clinical resource allocation is especially pertinent for a dis-
51 ease like COVID-19, where undetected presymptomatic transmission caused by mismatched latent
52 and incubation periods (10, 11) as well as potentially large numbers of undetected totally asymp-
53 tomatic spreaders (12, 13, 14, 15) present significant barriers to controllability.

54 Given the complexity of real-world disease dynamics with features like symptom-based test-
55 ing and pre- and asymptomatic transmission, simplified compartmental mathematical models can
56 provide powerful tools for analyzing and optimizing control strategies in the face of resource lim-
57 itations. However, overly simplistic models can yield erroneous conclusions regarding real-world

58 control strategies, so one must carefully balance model simplicity against the complex realistic
59 elements most relevant to the problem at hand. Conventional compartmental COVID-19 control
60 models are typically based on systems of ordinary differential equations (ODE's) (16, 17, 18, 19, 20,
61 21, 22, 23, 24, 25). While ODE disease models provide a level of mathematical tractability, they
62 necessitate the coupling of symptom status to specific model compartments, and this structural
63 constraint can result in unnatural or unrealistic representations of symptom onset and presym-
64 tomatic transmission with potential unintended consequences on model behavior and real-world
65 interpretations. This limitation is especially problematic when modeling controls like clinical and
66 non-clinical testing strategies that are directly tied to symptom status.

67 ODE models for COVID-19 have generally addressed symptom onset and presymptomatic trans-
68 mission by one of two broad schemes, both of which have their own drawbacks. One class of models
69 simply ignores the potential for presymptomatic transmission by having infected individuals tran-
70 sition from an exposed non-symptomatic non-infectious compartment to an infectious symptomatic
71 compartment, often with an additional infection channel comprised of permanently asymptomatic
72 infected individuals. Such models have been used to analyze testing, contact tracing, and quar-
73 antine control strategies (16, 17), particularly in the context of limited resource constraints (18),
74 along with vaccination control (19) and non-pharmaceutical interventions like masking and social
75 distancing (20, 21). Although useful as simple baseline examples, these models may overestimate
76 the efficacy of symptom-based COVID-19 controls due to the absence of presymptomatic transmis-
77 sion. A second more complicated class of ODE models includes a presymptomatic compartment
78 where individuals are infectious but not yet symptomatic before transitioning to an infectious
79 symptomatic compartment (22, 23, 24, 25). This approach, while more realistic, presents chal-
80 lenges when interpreting results for real world decision making via comparisons to the simpler class
81 of models. Specifically, when multiple infectious stages are incorporated into an ordinary differ-
82 ential equation model, the total infectious period is no longer exponentially distributed (as would
83 occur for a single infectious stage), but is instead more similar to a gamma or Weibull distribu-
84 tion (26), and such non-exponential distributions have been shown to be more difficult to control
85 with identification-isolation strategies as compared to exponential distributions (27). Thus, it is
86 unclear to what degree differences in output between models with and without presymptomatic
87 compartments are due to presymptomatic transmission itself or to the presence of non-exponential

88 infectious periods, and this presents a barrier to interpreting model results for real-world decision
89 making. Furthermore, when a totally asymptomatic infection channel is included, one must either
90 add a fictitious presymptomatic compartment for this class or accept a major qualitative difference
91 between the infectious period distributions of those who will never and those who will eventually
92 show symptoms (exponential vs non-exponential). Either option may have important impacts on
93 model behavior, yet to our knowledge, this issue may has not been explicitly addressed in the
94 literature. Finally, the class of models with presymptomatic compartments can not be adapted
95 to other diseases for which infectiousness peaks well after symptom onset (such as with the 2003
96 SARS coronavirus (28, 29)) without significant changes to model structure, and this complicates
97 any comparative mathematical analysis of diseases which are fundamentally similar to one another
98 aside from changes in latent-incubation period mismatch. This deficit may be particularly prob-
99 lematic for utilizing mathematical models to inform real-world control strategies for new emerging
100 epidemics based on the lessons learned from COVID-19.

101 We address these shortcomings by developing a partial integro differential equation model which
102 utilizes the age of infection to decouple symptom status from specific model compartments. Our
103 model is general in its ability to incorporate any latent, incubation, and infectious period distri-
104 bution, regardless of shape or relative timings of means, and is utilized to analyze the original,
105 delta, and omicron variants as well as a spectrum of other generically parameterized diseases all
106 under a single lens. We incorporate a testing and quarantine control strategy which uses testing
107 resources to identify infected individuals and remove them from the population while accounting
108 for factors like contact tracing, limited population accessibility, and biases towards test-positive
109 results. Our control assumes a fixed maximum testing capacity that must be allocated between
110 clinical testing targeted at symptomatic individuals and non-clinical testing targeted at pre- and
111 asymptomatic individuals. We analyze how controllability and optimal allocation strategies for
112 reducing total infection size behave as functions of resource availability, testing quality, and dis-
113 ease characteristics. In general, we find that most factors that reduce controllability also call for
114 a smaller share of resources to be devoted to non-clinical testing in optimal strategies. However,
115 although presymptomatic transmission is found to reduce controllability, whether or not it reduces
116 the role of non-clinical testing in optimal strategies depends on a complicated relationship between
117 latent-incubation offset, disease transmissibility, and latent period length. In particular, we find

118 that diseases with presymptomatic transmission do not necessarily call for a increase in non-clinical
119 testing resource allocation compared to diseases lacking presymptomatic transmission, despite the
120 fact that intuition would deem non-clinical testing to be of greater importance due to its the po-
121 tential to eliminate presymptomatic spreaders. Together, these results highlight how intuition for
122 disease control strategies based on qualitative disease characteristics may fail and thus emphasize
123 the need for mathematical modeling to prepare for and manage future epidemics.

124 **2 Methods**

125 We extend the previous ordinary differential equation (ODE) SEIR testing and quarantine model
126 of Calabrese and Demers (18) to a system of integro-partial differential equations (IPDE) which
127 explicitly incorporate the age of infection for infected classes. While our primary focus is COVID-
128 19, including the original, delta, and omicron variants, our system is general in its ability to account
129 for any set of latent, incubation, and infectiousness periods.

130 **2.1 Model outline**

131 **2.1.1 Uncontrolled transmission model**

132 We assume a homogeneously mixed system of N total susceptible, exposed, infectious, and recovered
133 individuals. Exposed and infectious classes are partitioned into those who will remain permanently
134 asymptomatic throughout the course of the infection and those who will eventually become symp-
135 tomatic at some point before recovery. Here, we take “asymptomatic” to mean genuinely exhibiting
136 no symptoms or exhibiting symptoms so minor that one would not typically consider themselves ill
137 or seek medical attention, and “symptomatic” to mean exhibiting visually identifiable symptoms
138 with moderate to critical illness. Upon infection, initially susceptible individuals S will enter either
139 the exposed permanently asymptomatic class E_A or the exposed eventually symptomatic class E_Y
140 with probabilities f_A and f_Y , respectively (throughout this paper, we use the abbreviations PA
141 and ES to denote permanently asymptomatic and eventually symptomatic individuals). While in
142 an exposed class, individuals are infected but not yet infectious and are thus unable to transmit
143 the disease to others. To account for the possibility of non-exponential waiting times between
144 infection sages, we continuously index exposed classes with the age of infection x . The number of

145 individuals in the exposed PA class at time t who have been infected between x and $x + dx$ units
 146 of time is denoted $e_A(t, x)dx$ such that the total number of exposed PA individuals $E_A(t)$ is given
 147 by $E_A(t) = \int_0^\infty dx e_A(t, x)$. The age of infection-indexed exposed ES class $e_Y(t, x)$ is defined analo-
 148 gously. PA and ES exposed individuals with infection age x transition to their respective infectious
 149 classes $a(t, x)$ and $y(t, x)$ at rate $\varepsilon(x)$. Infectious individuals enter into the recovered class R where
 150 they are no longer infectious and are assumed to attain permanent immunity at age of infection
 151 dependent recovery rate $r(x)$. Although there is some evidence suggesting that ES and PA indi-
 152 viduals recover from COVID-19 at different rates, disease progression in asymptomatic individuals
 153 is poorly understood, and conflicting studies have shown faster, similar, and slower viral clearance
 154 rates in asymptomatic versus symptomatic cases (30, 31). For simplicity, we therefore take $r(x)$
 155 to be equivalent for PA and ES infections. Likewise, we are aware of only one study suggesting
 156 different transitions rates from the exposed to infectious class for PA versus ES individuals (10),
 157 but the corresponding average waiting times differ by only 5%, so we assume exposed to infectious
 158 transition rates to be independent of the eventual presence or lack of symptoms. The dynamical
 159 equations for the uncontrolled transmission model are as follows:

$$\dot{S}(t) = -\lambda_A \beta \frac{A(t)}{N} S(t) - \lambda_Y \beta \frac{Y(t)}{N} S(t) \quad (1a)$$

$$\partial_t e_A(t, x) + \partial_x e_A(t, x) = -\varepsilon(x) e_A(t, x) \quad (1b)$$

$$e_A(t, 0) = f_A \left(\lambda_A \beta \frac{A(t)}{N} S(t) + \lambda_Y \beta \frac{Y(t)}{N} S(t) \right) \quad (1c)$$

$$\partial_t e_Y(t, x) + \partial_x e_Y(t, x) = -\varepsilon(x) e_Y(t, x) \quad (1d)$$

$$e_Y(t, 0) = f_Y \left(\lambda_A \beta \frac{A(t)}{N} S(t) + \lambda_Y \beta \frac{Y(t)}{N} S(t) \right) \quad (1e)$$

$$\partial_t a(t, x) + \partial_x a(t, x) = \varepsilon(x) e_A(t, x) - r(x) a(t, x) \quad (1f)$$

$$a(t, 0) = 0 \quad (1g)$$

$$\partial_t y(t, x) + \partial_x y(t, x) = \varepsilon(x) e_Y(t, x) - r(x) y(t, x) \quad (1h)$$

$$y(t, 0) = 0 \quad (1i)$$

$$\dot{R}(t) = \int_0^\infty dx \left(r(x) a(t, x) + r(x) y(t, x) \right) \quad (1j)$$

160

$$E_A(t) = \int_0^\infty dx e_A(t, x), \quad E_Y(t) = \int_0^\infty dx e_Y(t, x), \quad (1k)$$

$$A(t) = \int_0^\infty dx a(t, x), \quad Y(t) = \int_0^\infty dx y(t, x).$$

161 In the above equations, overdots denote ordinary derivatives with respect to time t , β denotes the
162 average number of contacts made per unit time by an individual, N is the total population size, and
163 λ_A and λ_Y denote the transmission probability per susceptible-infectious contact for the PA and
164 ES classes, respectively (for simplicity, we assume transmission probability to be independent of
165 the age of infection). The boundary terms $e_A(t, 0)$ and $e_Y(t, 0)$ denote the rates of newly generated
166 infections and thus represent to individuals with infection age $x = 0$. The boundary terms $a(t, 0)$
167 and $y(t, 0)$ are zero due to the fact that every infected individual will spend at least some time in an
168 exposed class before becoming infectious and will therefore never enter an infectious class with an
169 infection age $x = 0$. The integrals in Eq. (1k) relate the total number of individuals in an infected
170 class to the corresponding distribution over the age of infection.

171 2.1.2 Symptom onset

172 The model in Eq. (1) makes no assumptions regarding the onset of symptoms in infected individ-
173 uals. This modeling choice is based on the fact that the natural dynamics of disease transmission
174 (absent interventions or controls explicitly correlated with symptom status) depend fundamentally
175 on infectious states rather than symptom states. In our IPDE model, symptoms are an incidental
176 background state which need not be represented by separate pre- and post-symptom onset com-
177 partments for each infected compartment as would be required in an ordinary differential equation
178 (ODE) model. We utilize the age of infection in the ES classes to the define the symptomatic
179 population $X_S(t)$ by the following integral:

$$X_S(t) = \int_0^\infty dx \left(P_e(x) e_Y(t, x) + P_y(x) y(t, x) \right). \quad (2)$$

180 The functions $P_e(x)$ and $P_y(x)$ denote the respective probabilities for exposed and infectious in-
181 dividuals to show symptoms by infection day x . These probabilities likewise determine the non-
182 symptomatic infected population $X_N(t)$ as follows:

$$X_N(t) = E_A(t) + A(t) + \int_0^\infty dx \left((1 - P_e(x)) e_Y(t, x) + (1 - P_y(x)) y(t, x) \right). \quad (3)$$

183 The non-symptomatic infected population is comprised of all PA infected individuals plus the ES
184 infected individuals who are not yet showing symptoms.

185 In our simulations, we consider two assumptions for $P_e(x)$ and $P_y(x)$, “correlated symptoms”
186 and “incubation symptoms:”

$$\text{Correlated Symptoms: } P_e(x) = 0, P_y(x) = 1. \quad (4)$$

$$\text{Incubation Symptoms: } P_e(x) = P_y(x) = \int_0^x dx' f_I(x').$$

187 The correlated symptoms assumption defines symptom onset to occur in perfect correlation with
188 infectiousness onset. Here, there is no possibility of pre-symptomatic transmission or pre-infectious
189 symptom onset, and the symptomatic population is the entire ES infectious class. This assumption
190 is equivalent to the symptom assumptions of our previous ODE testing and quarantine COVID-19
191 model in (18). The incubation symptoms assumptions defines $P_e(x)$ and $P_y(x)$ to be the cumu-
192 lative distribution function of an incubation period distribution $f_I(x)$. Here, $f_I(x)dx$ denotes the
193 probability for an ES individual to begin showing symptoms between age of infection x and $x + dx$.
194 The flow diagram in Fig. 1 summarizes the progression of infectious and symptomatic states in the
195 uncontrolled transmission model.




Figure 1: Schematic indicating the flow of infectious and symptomatic states in our uncontrolled transmission model. Upon infection, susceptible individuals S move into either the permanently asymptomatic (PA) exposed class E_A or the eventually symptomatic (ES) exposed class E_Y with an initial age of infection $x = 0$. As individuals linger in the exposed classes, their ages of infection increase, and transitions to the PA infectious class A and ES infectious class Y occur at infection age dependent transition rate $\varepsilon(x)$. Infectious individuals then transition to the recovered class R at the infection-age-dependent transition rate $r(x)$. Symptom status appears as background state indicated by the red and green boxes. For ES exposed and infectious individuals with infection age x , a fraction $P_e(x)$ and $P_y(x)$, respectively, will be in the symptomatic state X_S , while the remaining fractions $1 - P_e(x)$ and $1 - P_y(x)$ will be in the non-symptomatic state X_N . The PA classes E_A and A remain in the non-symptomatic state X_N until recovery.

196 2.1.3 Testing and quarantine transmission model

197 We adapt the resource allocation testing and quarantine control framework from the ODE model of
198 (18) to our IPDE disease model. Testing identifies and transfers infected individuals to a quarantine
199 class Q where they remain isolated from contacts until recovery and are unable to generate new
200 transmissions. We assume a finite testing resource represented by the testing capacity C , defined
201 as the maximum per capita number of tests able to be administered and processed per day. A frac-
202 tion ρ of the testing capacity is allocated to non-clinical testing for identifying non-symptomatic
203 infected individuals, while the remaining fraction $1 - \rho$ is allocated to clinical testing for identifying
204 symptomatic infected individuals. Clinical testing is conducted only on individuals showing suffi-
205 ciently severe visually identifiable symptoms, while non-clinical testing is accessible to the general
206 public. The actual rate at which tests are administered and processed for the two testing categories
207 is dependent on the *testing demand*, i.e. on the number of people eligible for and actively seeking
208 testing. Here, we provide the functional forms of test administration and processing rates for clini-
209 cal and non-clinical testing and sketch the reasoning behind their formulation. Further details are
210 elucidated in (18).

211 The average time required for a non-clinical test to be administered and processed for a single
212 individual is denoted τ_N such that the average administration and processing rate is given by $1/\tau_N$:

$$\tau_N^{-1} = \begin{cases} 0, & C = 0 \text{ or } \rho = 0 \\ \left[\tau + \kappa \frac{X_N(t) + (1-\eta)(S(t)+U(t))}{\rho C N} \right]^{-1}, & \text{otherwise} \end{cases} \quad (5)$$

213 Non-clinical testing enters the disease model by transferring a fraction κ of the non-symptomatic
214 infected population (either pre- or asymptomatic) to the quarantined class Q at rate τ_N^{-1} . The case
215 $C = 0$ corresponds to no testing capacity and thus no control, while the case $\rho = 0$ corresponds to
216 all resources being devoted to clinical testing which reduces the non-clinical testing rate to zero.
217 The quantity τ is the *intrinsic testing time*, defined as average time required for an individual get
218 to a testing center, get tested, and receive results absent of delays or backlogs due to other patients.
219 We take this value to be equal to one day. The testing demand for non-clinical testing is defined
220 as a fraction κ the non-symptomatic population $X_N(t)$ in Eq. (3) as well as a fraction $\kappa(1 - \eta)$
221 of the uninfected population $S(t) + U(t)$. Here, $U(t)$ represents individuals who were previously

222 infected and subsequently recovered without being tested and are thus unaware that they have
223 immunity (we assume recovered individuals who were tested and quarantined know that they
224 have immunity and therefore exclude themselves from future testing). The *accessibility parameter*
225 $\kappa \in (0, 1]$ represents the fraction of the total population open to and compliant with non-clinical
226 testing, and the *concentration parameter* $\eta \in [0, 1)$ represents the degree to which testing is focused
227 on or biased towards infected individuals. A purely random population monitoring program which
228 reaches all members of the population corresponds to $\kappa = 1$ and $\eta = 0$. Any factor that influences
229 a given test such that it will be more likely applied to an infected individual as compared to purely
230 random sampling will increase η . For example, those who suspect a recent disease exposure may
231 be both more likely to seek testing and more likely to test positive compared a randomly selected
232 individual, and this influence will focus testing towards the X_N population and away from the $S+U$
233 population. Likewise, a highly effective contact tracing program may result in a relatively large
234 value of η , but there may be many individuals unwilling to participate in government or health
235 agency efforts, so the corresponding value of κ may be relatively small. Generally, the differing
236 behavioral characteristics of individuals and differing testing policies of local governments unique
237 to differing regions will correspond to a variety of concentration and accessibility levels, so we will
238 analyze model results for a wide array of κ and η values. The analysis in (18) shows that η can be
239 estimated from data comparing test-positive to disease prevalence rates, and that $\eta = 0.95$ is an
240 upper bound on optimistically achievable values.

241 The average time required for a clinical test to be administered and processed for a single
242 symptomatic individual is denoted τ_C such that the average administration and processing rate is
243 given by $1/\tau_C$:

$$\tau_C^{-1} = \begin{cases} 0, & C = 0 \text{ or } \rho = 1 \\ \left[\tau + \frac{X_S(t)}{(1-\rho)CN} \right]^{-1}, & \text{otherwise} \end{cases}, \quad (6)$$

244 Clinical testing enters the disease model by transferring symptomatic individuals to the quarantine
245 class Q at rate τ_C^{-1} . The case $C = 0$ corresponds to no control, while the case $\rho = 1$ corresponds
246 to all resources being devoted to non-clinical testing which reduces the clinical testing rate to zero.
247 In contrast to non-clinical testing, clinical testing is assumed to have full concentration on and full

248 accessibility to the target infected population, meaning that the testing demand is comprised only
 249 of the symptomatic population X_S and includes no uninfected individuals. We base this on the
 250 assumption that all individuals in the ES classes who are currently showing symptoms are all ill
 251 enough to seek medical attentions (full advisability), and that due to the presence of strong visually
 252 identifiable symptoms and the lack of secondary diseases in our model, there is no chance of using
 253 a clinically allocated test on an uninfected individual (full concentration). In this sense, clinical
 254 testing acts as a verification tool, while non-clinical testing acts as an identification tool.

255 For both testing types, when testing demand is very low, tests are administered and processed
 256 at maximum rates $\tau_C^{-1} \approx \tau^{-1}$ and $\tau_N^{-1} \approx \tau^{-1}$ per individual, and the total number of clinical
 257 tests conducted per day grows linearly with the size of the symptomatic population. As demand
 258 increases, supply limitations and patient backlogs cause τ_C^{-1} and τ_N^{-1} to decrease towards zero, and
 259 the total number of clinical and non-clinical tests conducted per day saturates to $(1 - \rho)CN$ and
 260 ρCN , respectively, as testing demand approaches infinity. The full model equations with testing
 261 and quarantine control are given in Eq. (7) and a corresponding flow diagram is given in Fig. 2.
 262 Table 1 summarizes the definitions of all control-related parameters.

$$\dot{S}(t) = -\lambda_A \beta \frac{A(t)}{N - Q(t)} S(t) - \lambda_Y \beta \frac{Y(t)}{N - Q(t)} S(t) \quad (7a)$$

$$\partial_t e_A(t, x) + \partial_x e_A(t, x) = -\varepsilon(x) e_A(t, x) - \kappa \tau_N^{-1} e_A(t, x) \quad (7b)$$

$$e_A(t, 0) = f_A \left(\lambda_A \beta \frac{A(t)}{N - Q(t)} S(t) + \lambda_Y \beta \frac{Y(t)}{N - Q(t)} S(t) \right) \quad (7c)$$

$$\begin{aligned} \partial_t e_Y(t, x) + \partial_x e_Y(t, x) &= -\varepsilon(x) e_Y(t, x) - \tau_C^{-1} P_e(x) e_Y(t, x) \\ &\quad - \tau_N^{-1} \kappa (1 - P_e(x)) e_Y(t, x) \end{aligned} \quad (7d)$$

$$e_Y(t, 0) = f_Y \left(\lambda_A \beta \frac{A(t)}{N - Q(t)} S(t) + \lambda_Y \beta \frac{Y(t)}{N - Q(t)} S(t) \right) \quad (7e)$$

$$\partial_t a(t, x) + \partial_x a(t, x) = \varepsilon(x) e_A(t, x) - r(x) a(t, x) - \tau_N^{-1} \kappa a(t, x) \quad (7f)$$

$$a(t, 0) = 0 \quad (7g)$$

$$\begin{aligned} \partial_t y(t, x) + \partial_x y(t, x) &= \varepsilon(x) e_Y(t, x) - r(x) y(t, x) - \tau_C^{-1} P_y(x) y(t, x) \\ &\quad - \tau_N^{-1} \kappa (1 - P_y(x)) y(t, x) \end{aligned} \quad (7h)$$

$$y(t, 0) = 0 \quad (7i)$$

$$\partial_t q(t, x) + \partial_x q(t, x) = -r(x) q(t, x) + \tau_C^{-1} \left[P_e(x) e_Y(t, x) + P_y(x) y(t, x) \right] \quad (7j)$$

$$+ \tau_N^{-1} \kappa \left[e_A(t, x) + a(t, x) + (1 - P_e(x)) e_Y(t, x) + (1 - P_y(x)) y(t, x) \right]$$

$$q(t, 0) = 0 \tag{7k}$$

$$\dot{U}(t) = \int_0^\infty dx \left(r(x) a(t, x) + r(x) y(t, x) \right) \tag{7l}$$

$$\dot{R}(t) = \int_0^\infty dx \left(r(x) a(t, x) + r(x) y(t, x) + r(x) q(t, x) \right) \tag{7m}$$

263

$$E_A(t) = \int_0^\infty dx e_A(t, x), \quad E_Y(t) = \int_0^\infty dx e_Y(t, x), \tag{7n}$$

$$A(t) = \int_0^\infty dx a(t, x), \quad Y(t) = \int_0^\infty dx y(t, x), \quad Q(t) = \int_0^\infty dx q(t, x).$$

Parameter	Name	Meaning
C	Testing capacity	Maximum number of tests able to be administered and processed per day per capita
τ	Testing time	Average amount of time required for an individual be tested (including procrastination, travel time, processing time, etc.) absent of backlogs or delays due to other patients
ρ	Strategy parameter	Fraction of testing capacity devoted to non-clinical testing
η	Concentration parameter	$(1 - \eta)$ = Degree to which non-clinical testing resources are utilized on uninfected individuals
κ	Accessibility parameter	Fraction of eligible population open to and compliant with non-clinical testing

Table 1: Testing and quarantine control parameter definitions

264




Figure 2: Flow diagram for the testing and quarantine control model in Eq. (7). The symptomatic population X_S and fraction κ of the non-symptomatic population X_N transition to the quarantine class Q by clinical and non-clinical testing, respectively, at rates τ_C^{-1} and τ_N^{-1} . Quarantined individuals transition to the recovered class R at age of infection dependent rate $r(x)$. The subset U of the recovered class represents individuals who were previously infected and subsequently recovered without testing and quarantine and are thus unaware that they have obtained immunity.

265 2.1.4 Transition rates

266 The transition rates $\varepsilon(x)$ and $r(x)$ are determined by probability distributions for infection ages
 267 at which transitions between disease states occur. Specifically, letting $f_\varepsilon(x)$ denote the probability
 268 density for an infected individual to transition from exposed to infectious at infection age x , and
 269 letting $f_r(x)$ denote the probability density for an infectious individual to transition to recovered
 270 at infection age x , the corresponding transition rates are defined as follows:

$$\varepsilon(x) = \frac{f_\varepsilon(x)}{1 - \int_0^x dx' f_\varepsilon(x')}, \quad (8)$$

$$r(x) = \frac{f_r(x)}{1 - \int_0^x dx' f_r(x')}. \quad (9)$$

271 These transition rates represent conditional probability densities for an individual to transition to
 272 the next disease stage on infection day x given that they are still in the preceding disease stage up
 273 to day x . The probability densities for the infectious period duration and total infection duration,
 274 denoted $f_{inf}(x)$ and $f_{tot}(x)$, respectively, can be written in terms of $f_\varepsilon(x)$ and $f_r(x)$ as follows:

$$f_{inf}(x) = \int_0^\infty ds f_\varepsilon(s) \frac{f_r(x+s)}{1 - \int_0^s ds' f_r(s')}, \quad (10)$$

$$f_{tot}(x) = \int_0^x ds f_\varepsilon(s) \frac{f_r(x)}{1 - \int_0^s ds' f_r(s')}. \quad (11)$$

275 To clarify, $f_{tot}(x)dx$ represents the probability for a newly infected individual to remain infected for
 276 a total duration between x and $x+dx$ days, $f_{inf}(x)dx$ represents the probability for that individual
 277 to be infectious (i.e. contagious) for a total duration between x and $x+dx$ days over the course
 278 of their infection, and $f_r(x)dx$ represents the probability for that individual to recover between
 279 infection days x and $x+dx$ given that they have already entered into an infectious state. If $f_r(x)$ is
 280 assumed to be an exponential distribution with mean $1/r$, $r(x)$ reduces to a constant $r(x) = r$ while
 281 $f_{inf}(x)$ becomes equivalent to $f_r(x)$. Likewise, if $f_\varepsilon(x)$ is exponential with mean $1/\varepsilon$, $\varepsilon(x)$ reduces
 282 to a constant $\varepsilon(x) = \varepsilon$. If both $f_r(x)$ and $f_\varepsilon(x)$ are exponential, $f_{tot}(x)$ becomes a two parameter
 283 hypoexponential distribution with parameters ε and r . The exponential distribution assumptions
 284 taken together with the correlated symptoms assumption in Sec. 2.1.2 reduce the IPDE testing and
 285 quarantine model in Eq. (7) to the ODE testing and quarantine model in (18).

286 2.2 Distribution and parameter values

287 2.2.1 COVID-19 variants

288 The distributions from which the transition rates $\varepsilon(x)$ and $r(x)$ are calculated, as well as the incu-
289 bation period distribution, are based on epidemiological data for the original, delta, and omicron
290 COVID-19 variants. The incubation period distribution $f_I(x)$ is a widely studied quantity for the
291 early strains of COVID-19 which has been variously fit to log-normal, gamma, or Weibull distri-
292 butions (32, 33, 34, 35, 36, 37). The latent period distribution $f_\varepsilon(x)$ and post-infectiousness onset
293 recovery day distribution $f_r(x)$ are comparatively less well studied. For the original COVID-19
294 strain and delta variant, we utilize the results of Xin et al. (10) and Kang et al. (11), respectively,
295 which estimate both f_ε and f_I to be gamma distributions. We are aware of only one data-based
296 study estimating the incubation period distribution for the omicron variant, Tanaka et al. (38),
297 which fits to a log-normal distribution with median 2.8 days. Other investigations estimating me-
298 dians but not distributions have likewise obtained results approximately equal to 3 days (39, 40). To
299 maintain consistency with the original and delta variants, we assume f_I for omicron to be gamma
300 distributed with mean and variance comparable to that of (38). We are unaware of any existing
301 estimates for the omicron variant's latent period distribution, so we assume a gamma distribution
302 with mean 1.5 days shorter than that of the incubation period. For all variants, we are unaware
303 of any studies that directly estimate the post-infectiousness onset recovery day distribution $f_r(x)$.
304 However, viral culturing studies have consistently found live viral isolation to cease between 9 and
305 10 days post-symptom onset (30, 31, 41). We therefore assume a gamma distribution for $f_r(x)$ with
306 mean $\langle f_r \rangle = \langle f_I \rangle + 9.5$ days for each variant, and we assume a scale parameter of 0.25 days to give
307 tight distributions with relatively small interquartile ranges as indicted in (41).

308 To assess the impact of the PDE elements of our model relative to the corresponding ODE
309 model, we will compare simulation results under exponential and gamma distribution assumptions
310 for f_ε and f_r . Likewise, to assess the impact of pre-symptomatic transmission on disease controlla-
311 bility, we will compare model results between the correlated symptoms and incubation symptoms
312 assumptions in Eq. (4). The means $\langle f_\varepsilon \rangle$ are taken to be equivalent under the exponential and
313 gamma assumptions, while we set $\langle f_r \rangle = \langle f_I \rangle - \langle f_\varepsilon \rangle + 9.5$ days under the exponential assumption
314 as compared to $\langle f_r \rangle = \langle f_I \rangle + 9.5$ days under the gamma assumption. This difference ensures that

315 the mean infectious period duration $\langle f_{inf} \rangle$ and mean total infection time $\langle f_{tot} \rangle$ are essentially un-
316 changed by the different assumptions on f_r . The means and standard deviations of f_ε , f_r , and f_I ,
317 as well as that of the resultant distributions f_{inf} and f_{tot} , are given in Tables 2, 3, and 4 for the
318 original, delta, and omicron COVID variants, respectively. Plots depicting the shapes of f_ε , f_r ,
319 and f_I for the three variants are given in Fig. 3. For all variants and distribution assumptions,
320 the average infectious period is approximately 11 days while the average latent period is approx-
321 imately 1.5 days shorter than the average incubation period, thus indicating an average 1.5 day
322 presymptomatic transmission window under the incubation symptoms assumption. The mean total
323 infection duration decreases from the original to delta to omicron variant.

324 The remaining model parameters and values are summarized in Table 5. For all COVID vari-
325 ants, the PA and ES population fractions, f_A and f_Y , respectively, are highly uncertain parameters,
326 as estimates based on both modeling and clinical data place f_A anywhere from less than 1% to
327 90% (12, 13, 14, 15). Further, the value of f_A will depend precisely on our definition of the differ-
328 ence between the moderate to critical symptoms exhibited by the ES class versus the mild to no
329 symptoms exhibited by the PA class. Evidence has suggested the majority of COVID cases to be
330 mild (42, 43), so based on these observations, we choose $f_A = 0.75$ and $f_Y = 0.25$. Likewise, the
331 relative values of the PA and ES transmission probabilities, λ_A and λ_Y , respectively, are highly
332 uncertain. Various studies have show that non-symptomatic individuals are as, or less, infectious
333 than symptomatic individuals (13, 14), and that greater symptom severity correlates with higher
334 viral loads (13, 14, 42). Further, a study on the close contacts of index cases has suggested symp-
335 tomatic individuals to be more infectious than asymptomatic individuals (44). We therefore assume
336 $\lambda_Y = 2\lambda_A$. To determine absolute values, we assume an average contact rate of $\beta = 4$ per day
337 and scale λ_A such that the model's uncontrolled basic reproduction number under the exponential
338 distribution assumptions (i.e. equivalent ODE model), denoted R_0^{un} , matches values taken from the
339 literature (see the Supplementary Material section S1 and S2 for a derivation and discussion of the
340 basic reproduction number). In other words, we define the following quantity:

$$R_0^{un} = f_A \frac{\beta \lambda_A}{r} + (1 - f_A) \frac{\beta \lambda_Y}{r}, \quad (12)$$

341 and then choose λ_A such that the above expression matches values for the different COVID variants,
 342 where the values of f_A and β are assumed, $1/r$ is equal to $\langle f_{inf} \rangle$ under the exponential distributions
 343 assumptions in Tables 2, 3, or 4, and where we assume $\lambda_Y = 2\lambda_A$. Based on estimates of R_0 during
 344 the initial phases of the pandemic (45, 46, 47), we set $R_0^{un} = 3.0$ for the original COVID variant.
 345 Combining estimates from (11, 48, 49), we set $R_0^{un} = 6.4$ for the delta variant. Based on (49, 50), we
 346 set $R_0^{un} = 9.5$ for the omicron variant. We note that changing exponential or gamma distribution
 347 assumptions for f_r and f_ε have a negligible impact on actual model basic reproduction number (see
 348 Supplementary Material section S2), so R_0^{un} represents the uncontrolled basic reproduction number
 for all distribution and symptom onset assumptions.

Original Variant	f_ε Gamma Distribution	f_ε Exponential Distribution
f_r Gamma Distribution	$\langle f_\varepsilon \rangle = 5.48$ $\sigma_\varepsilon = 2.72$	$\langle f_\varepsilon \rangle = 5.48$ $\sigma_\varepsilon = 5.48$
	$\langle f_r \rangle = 16.38$ $\sigma_r = 2.02$	$\langle f_r \rangle = 16.38$ $\sigma_r = 2.02$
	$\langle f_{inf} \rangle = 10.92$ $\sigma_{inf} = 3.34$	$\langle f_{inf} \rangle = 11.26$ $\sigma_{inf} = 4.81$
	$\langle f_{tot} \rangle = 16.40$ $\sigma_{tot} = 2.02$	$\langle f_{tot} \rangle = 16.74$ $\sigma_{tot} = 2.69$
f_r Exponential Distribution	$\langle f_\varepsilon \rangle = 5.48$ $\sigma_\varepsilon = 2.72$	$\langle f_\varepsilon \rangle = 5.48$ $\sigma_\varepsilon = 5.48$
	$\langle f_r \rangle = 10.90$ $\sigma_r = 10.90$	$\langle f_r \rangle = 10.90$ $\sigma_r = 10.90$
	$\langle f_{inf} \rangle = 10.90$ $\sigma_{inf} = 10.90$	$\langle f_{inf} \rangle = 10.90$ $\sigma_{inf} = 10.90$
	$\langle f_{tot} \rangle = 16.38$ $\sigma_{tot} = 11.23$	$\langle f_{tot} \rangle = 16.38$ $\sigma_{tot} = 12.20$
f_I Gamma Distribution: $\langle f_I \rangle = 6.88$ $\sigma_I = 3.32$		

Table 2: Original variant distributions based on Refs. (30, 31, 10, 41). Simulations assume either exponential or gamma distributions for f_ε and f_r with means $\langle \rangle$ and standard deviations σ as indicated in units of days. Means and standard deviations for the resulting infectious period distribution f_{inf} and total infection duration distribution f_{tot} are likewise indicated. The incubation symptoms assumption utilizes a gamma distributed incubation period length f_I with indicated mean and standard deviation in units of days.

349

Delta Variant	f_ε Gamma Distribution	f_ε Exponential Distribution
f_r Gamma Distribution	$\langle f_\varepsilon \rangle = 4.00$ $\sigma_\varepsilon = 2.22$	$\langle f_\varepsilon \rangle = 4.00$ $\sigma_\varepsilon = 4.00$
	$\langle f_r \rangle = 15.30$ $\sigma_r = 1.96$	$\langle f_r \rangle = 15.30$ $\sigma_r = 1.96$
	$\langle f_{inf} \rangle = 11.30$ $\sigma_{inf} = 2.94$	$\langle f_{inf} \rangle = 11.43$ $\sigma_{inf} = 4.02$
	$\langle f_{tot} \rangle = 15.30$ $\sigma_{tot} = 1.96$	$\langle f_{tot} \rangle = 15.43$ $\sigma_{tot} = 2.14$
f_r Exponential Distribution	$\langle f_\varepsilon \rangle = 4.00$ $\sigma_\varepsilon = 2.22$	$\langle f_\varepsilon \rangle = 4.00$ $\sigma_\varepsilon = 4.00$
	$\langle f_r \rangle = 11.30$ $\sigma_r = 11.30$	$\langle f_r \rangle = 11.30$ $\sigma_r = 11.30$
	$\langle f_{inf} \rangle = 11.30$ $\sigma_{inf} = 11.30$	$\langle f_{inf} \rangle = 11.30$ $\sigma_{inf} = 11.30$
	$\langle f_{tot} \rangle = 15.30$ $\sigma_{tot} = 11.51$	$\langle f_{tot} \rangle = 15.30$ $\sigma_{tot} = 11.99$
f_I Gamma Distribution: $\langle f_I \rangle = 5.80$ $\sigma_I = 3.02$		

Table 3: Delta variant distributions based on Refs. (30, 31, 11, 41). Meanings of quantities are as described in Table 2.

Omicron Variant	f_ε Gamma Distribution	f_ε Exponential Distribution
f_r Gamma Distribution	$\langle f_\varepsilon \rangle = 1.50$ $\sigma_\varepsilon = 1.00$	$\langle f_\varepsilon \rangle = 1.50$ $\sigma_\varepsilon = 1.50$
	$\langle f_r \rangle = 12.50$ $\sigma_r = 1.77$	$\langle f_r \rangle = 12.50$ $\sigma_r = 1.77$
	$\langle f_{inf} \rangle = 11.00$ $\sigma_{inf} = 2.03$	$\langle f_{inf} \rangle = 11.00$ $\sigma_{inf} = 2.31$
	$\langle f_{tot} \rangle = 12.50$ $\sigma_{tot} = 1.77$	$\langle f_{tot} \rangle = 12.50$ $\sigma_{tot} = 1.77$
f_r Exponential Distribution	$\langle f_\varepsilon \rangle = 1.50$ $\sigma_\varepsilon = 1.00$	$\langle f_\varepsilon \rangle = 1.50$ $\sigma_\varepsilon = 1.50$
	$\langle f_r \rangle = 11.00$ $\sigma_r = 11.00$	$\langle f_r \rangle = 11.00$ $\sigma_r = 11.00$
	$\langle f_{inf} \rangle = 11.00$ $\sigma_{inf} = 11.00$	$\langle f_{inf} \rangle = 11.00$ $\sigma_{inf} = 11.00$
	$\langle f_{tot} \rangle = 12.50$ $\sigma_{tot} = 11.04$	$\langle f_{tot} \rangle = 12.50$ $\sigma_{tot} = 11.10$
f_I Gamma Distribution: $\langle f_I \rangle = 3.00$ $\sigma_I = 1.22$		

Table 4: Omicron variant distributions based on Refs. (30, 31, 38, 41). Meanings of quantities are as described in Table 2.




Figure 3: Latent period distributions $f_\varepsilon(x)$, incubation period distributions $f_I(x)$, and post-infectiousness onset recovery day distributions $f_r(x)$ as functions of the age of infection x for the original, delta, and omicron variants of COVID-19. Model simulations will consider combinations of exponential (dotted lines) and gamma (solid lines) distribution assumptions for f_ε and f_r , as well as an incubation period symptom onset assumption using a gamma distribution for f_I or a correlated symptom assumption where symptom onset coincides exactly with the onset of infectiousness.

350 2.2.2 Generic diseases

351 In addition to the COVID-19 variants, we consider a generic disease similar to the original variant
 352 but with a variable offset between the mean incubation and latent period. Defining $z = \langle f_I \rangle - \langle f_\varepsilon \rangle$,
 353 we consider both positive and negative z values. Positive z values represent diseases for which
 354 symptom onset typically occurs after infectiousness onset, thus allowing for significant levels of pre-
 355 symptomatic transmission as occurs, for example, with the viruses SARS-CoV-2 and 2009 pandemic
 356 influenza H1N1 (51, 52, 28). Negative z values indicate viruses like SARS-CoV and MERS-CoV
 357 for which symptom onset typically occurs well before infectiousness onset or peak infectivity, thus
 358 making pre-symptomatic transmission insignificant or absent entirely (28, 29). In all cases, we
 359 assume fixed gamma distributions for f_ε and f_r similar to those of the original COVID-19 variant
 360 and vary z by considering different gamma distributed incubation periods f_I . Assumed means and
 361 standard deviations for f_ε , f_r , and f_I for the specific z values under consideration are given in
 362 Table 6, and the distributions are pictured graphically in Fig. 4. Remaining model parameters are
 363 taken to be equivalent to those of COVID-19 in Table 5, where we will consider a variety of R_0^{un}
 364 and corresponding λ_A values.

Parameter	Name	Meaning	Value	Refs
R_0^{un}	Uncontrolled basic reproduction number	Model R_0 with no testing or quarantine control	3.0 (Original Variant) 6.4 (Delta Variant) 9.5 (Omicron Variant)	(11, 45, 46, 47, 48, 49, 50)
β	Contact rate	Average number of contacts per individual per unit time	4.0 (day)^{-1}	Assumed
λ_A	PA transmission probability	Probability of disease transmission per susceptible-permanently asymptomatic contact	0.055 (Original Variant) 0.113 (Delta Variant) 0.173 (Omicron Variant)	Inferred from R_0^{un}
λ_Y	ES transmission probability	Probability of disease transmission per susceptible-eventually symptomatic contact	$2\lambda_A$	(13, 14, 42, 44)
f_A	Asymptomatic fraction	Fraction of infections which remain mild or asymptomatic	0.75	(12, 13, 14, 15, 42, 43)
f_Y	Symptomatic fraction	Fraction of infections which become severe and symptomatic	$1 - f_A$	-
N	Population size	Total number of hosts (assumed fixed)	50000	Assumed

Table 5: Model parameter definitions and numerical values used for COVID-19 variants.

Offset	$z = -4.5$	$z = -3.0$	$z = -1.5$	$z = 0$	$z = 1.5$	$z = 3.0$	$z = 4.5$
$\langle f_I \rangle$	1.50	3.00	4.50	6.00	7.50	9.00	10.50
σ_I	1.22	1.91	2.27	2.83	2.83	2.83	2.83
$\langle f_\varepsilon \rangle = 6.00, \sigma_\varepsilon = 2.83 \quad \langle f_r \rangle = 17.00, \sigma_r = 2.06$ $\langle f_{inf} \rangle = 11.02, \sigma_{inf} = 3.45 \quad \langle f_{tot} \rangle = 17.02, \sigma_{tot} = 2.06$							

Table 6: Gamma distribution parameters for generic diseases with different offsets between mean incubation and latent periods denoted by $z = \langle f_I \rangle - \langle f_\varepsilon \rangle$. Means $\langle \cdot \rangle$, standard deviations σ , and z values are given in units of days.




Figure 4: Latent period distribution $f_\varepsilon(x)$, incubation period distributions $f_I(x)$, and post-infectiousness onset recovery day distribution $f_r(x)$ as functions of the age of infection x for generic diseases with different offsets z between mean incubation and latent periods indicated in units of days.

365 **2.3 Numerical integration and optimization**

366 We compute the discretized dynamical equations for the system (7) using the upwind scheme for
367 non-linear partial integro-differential equations with integral boundary conditions (53), and then
368 use the midpoint method to integrate the system forward in time. We assume initial infection
369 conditions $e_A(0, x)\Delta x = f_A$ and $e_Y(0, x)\Delta x = f_Y$ for $x \in [0, \Delta x]$, where $\Delta x = 1/6$ days is the
370 discretization length for the age of infection domain, and $e_A(0, x) = e_A(0, y) = 0$ for $x > \Delta x$. The
371 system is assumed otherwise to be initially completely susceptible such that $S(0) = N - 1$ and
372 $a(0, x) = y(0, x) = q(0, x) = R(0) = U(0) = 0$ for all x . Age of infection integrals are computed
373 using the trapezoid rule where we assume a finite domain with an upper bound $x_{max} = 80$ days
374 (the number of infected individuals who would otherwise recover after x_{max} is negligible for all
375 disease variants considered). We integrate the model equations from an initial time $t_0 = 0$ to final
376 time $t_f = 2$ years using a time step $\Delta t = 1/10$ days. When implementing testing and quarantine
377 control, we find optimal allocation strategies ρ for reducing the total infection size $S(t_0) - S(t_f)$
378 under a variety of C, η , and κ values using the *fmincon* function in *Matlab R2021b*.

379 **3 Results**

380 **3.1 Optimal total infection size reduction and disease controllability**

381 Figures 6 and 7 display total infection sizes under optimal resource allocation strategies as a func-
382 tion of testing capacity for the different COVID variants as well as the generic disease with z and
383 R_0^{un} comparable to that of delta and omicron variants ($z = 1.5$ days and $R_0^{un} = 6.4$ or 9.5). Curve
384 color and dashed pattern represent different combinations of assumptions regarding symptom onset
385 (incubation symptoms or correlated symptoms) and distributions for f_ϵ and f_r (gamma or expo-
386 nential) as detailed by the legend in Fig. 5. Different plots represent different disease variants and
387 different choices for η and κ values. The presented results focus on two particular cases: “random
388 testing” ($\kappa = 1.00, \eta = 0$) and “realistic testing” ($\kappa = 0.85, \eta = 0.75$). Random testing represents a
389 population-wide pure random sampling non-clinical testing program, while realistic testing repre-
390 sents a non-clinical testing scenario more likely to be encountered in the real world, where contact
391 tracing and natural biases result in increased testing of infected individuals but where some of the

392 population is inaccessible or resistant to testing efforts. The case of no control is represented at
393 zero testing capacity ($C = 0$). By definition, symptom onset assumptions and testing parameter
394 values have no influence on model outcomes at $C = 0$, but interestingly, we see that exponential
395 versus gamma distribution assumptions for f_ε and f_r have no meaningful impact on total infection
396 size at $C = 0$ even though model dynamics differ.

397 Generally, as the testing capacity C increases, Figs. 6 and 7 show that the total infection size
398 decreases when resources are distributed optimally. In particular, complete disease eradication is
399 possible at reasonably achievable testing capacities for a less infectious variant when non-clinical
400 testing can be effectively targeted at individuals who are actually infected (large η in Figs. 6b and
401 6d). However, if non-clinical testing does not target infected individuals (small η in Figs. 6a and
402 6c), or if the variant is of greater infectiousness (Fig. 7), eradication may not be achievable at
403 the reduced testing capacities available during the initial phases of a novel disease outbreak. The
404 accessibility κ has a smaller influence on reducing total infections compared to the concentration
405 η , and disease eradication may possible even for smaller accessibility levels (Fig. 6d). This result
406 emphasizes the importance of implementing effective contact tracing programs for COVID-like dis-
407 eases even if such programs can only reach a relatively small number of individuals.

408 Together, Figs. 6 and 7 exemplify the influences of symptom onset assumptions, period distribu-
409 tion assumptions, testing parameter values, and disease variant characteristics on disease control-
410 lability. By controllability, we specifically mean the amount of testing capacity required to achieve
411 a given reduction in total infection size. We consider a set ‘A’ of assumptions and parameters
412 to be less controllable than another set ‘B’ if set ‘A’ requires a larger testing capacity to reduce
413 total infection size to half, for example, of the uncontrolled value under optimal resource allocation
414 strategies (see Supplementary Material section S4 for alternative but equivalent measures of con-
415 trollability involving the basic reproduction number).


416 Gamma versus exponential distribution assumptions for f_r have a profound effect on controlla-
417 bility. Comparing a dashed curve (exponential) to a solid curve (gamma) of the same color in either
418 Fig. 6a, 6b, or 7 shows that the gamma assumption produces a large decrease in controllability
419 relative to the exponential assumption. On the other hand, the gamma assumption for f_ε increases
420 controllability relative to the exponential assumption. This is seen in Fig. 6a, 6b, or 7 by comparing
421 a solid orange curve to a solid blue curve or a solid purple curve to a solid gold curve, and likewise

422 for dashed curves. The effects of incubation symptom versus correlated symptom assumptions are
423 exemplified by comparing a solid gold to solid blue curve or solid purple to solid orange curve, and
424 likewise for dashed curves. Here, incubation symptom assumptions decrease controllability relative
425 to correlated symptom assumptions. Interestingly, for a given assumption on f_r , the decrease in
426 controllability due to incubation symptoms is nullified to some extent by the increase in controlla-
427 bility due to a gamma distributed f_ε such that solid (dashed) blue and purple curves can lie close
428 to one another bounded by solid (dashed) red and gold curves. In other words, the IPDE specific
429 assumptions for latent period length and symptom onset tend to counteract one another. However,
430 the full IPDE model (solid purple curve) generally shows a significant reduction in controllability
431 relative to the full ODE model (dashed blue curve).


432 The influences of the testing parameters η and κ on controllability are shown in Figs. 6c and
433 6d, where smaller values tend to decrease controllability. The influences of disease variant char-
434 acteristics are seen by comparing Fig. 6b to the corresponding curves in all plots in Fig. 7. Here,
435 the omicron COVID variant is significantly less controllable than the delta variant, and the delta
436 variant is moderately less controllable than the original variant. These controllability reductions
437 may be caused by either increases in transmissibility or decreases in the mean latent period length
438 associated with each COVID variant, where $R_0^{un} = 3.0, 6.4,$ and 9.5 and $\langle f_\varepsilon \rangle = 5.48, 4.00,$ and 1.50
439 days for the original, delta, and omicron variants, respectively (the mean incubation-latent offsets
440 z and mean infectious period lengths are approximately equal for all variants). The independent
441 influences of transmissibility and latent period length can be deduced using the generic disease in
442 Figs. 7c and 7d. Here, the mean latent period $\langle f_\varepsilon \rangle = 6.00$ days is comparable to that of the original
443 variant, and comparing Fig. 6b to Figs. 7c and 7d thus shows that increases in transmissibility
444 alone cause decreases in controllability. Likewise, comparing Fig. 7a and 7b to Fig. 7c and Fig. 7d,
445 respectively, shows that decreases in $\langle f_\varepsilon \rangle$ alone cause decreases in controllability. A summary of all
446 observed controllability reducing factors is given in Table 7.

	correlated symptoms	incubation symptoms	dashed line: $f_r(x)$ exponential solid line: $f_r(x)$ gamma
$f_\varepsilon(x)$ exponential			
$f_\varepsilon(x)$ gamma			


Figure 5: Legend for interpreting curve color and style in Figs. 6, 7, 8, 9, and 10. Different colors represent different combinations of exponential and gamma distribution assumptions for f_ε along with different assumptions for correlated versus incubation symptom onset as indicated by the colored table. Dashed lines indicate the exponential distribution assumption for f_r while solid lines indicate the gamma distribution assumption. The model with all IPDE elements is given by a solid purple curve while the ODE equivalent model is given by a dashed blue curve.




(a) Original Variant: Variable Distribution and Symptom Assumptions



(b) Original Variant: Variable Distribution and Symptom Assumptions




(c) Original Variant: Gamma Distribution and Incubation Symptom Assumptions




(d) Original Variant: Gamma Distribution and Incubation Symptom Assumptions


Figure 6: Total infection sizes under optimal allocation strategies as a function of testing capacity for the original COVID variant under a variety of symptom onset, period distribution, and testing parameter assumptions. The meaning of curve color and dashed versus solid curves is given in Fig. 5. Note the changes in x-axis scale for each plot.




(a) Delta Variant: Variable Distribution and Symptom Assumptions



(b) Omicron Variant: Variable Distribution and Symptom Assumptions



(c) Generic Disease $R_0^{un} = 6.4$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions



(d) Generic Disease $R_0^{un} = 9.5$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions

Figure 7: Total infection sizes under optimal allocation strategies as a function of testing capacity for the delta and omicron COVID variants, as well a generic disease similar to COVID-19, under a variety of symptom onset, period distribution, and testing parameter assumptions. The meaning of curve color and dashed versus solid curves is given in Fig. 5. The generic disease assumes R_0^{un} values equal to those of the delta and omicron COVID variants with a mean latent period $\langle f_\varepsilon \rangle = 6.00$ days comparable to that of the original variant, and assumes a incubation-latent offset $z = 1.5$ days similar to all COVID variants. Note the changes in x-axis scale for each plot.


Controllability reducing factors for COVID-like diseases
f_r gamma distribution
f_ε exponential distribution
reduction in non-clinical concentration η
reduction in non-clinical accessibility κ
increase in overall transmissibility (i.e. R_0^{un})
reduction in mean latent period $\langle f_\varepsilon \rangle$
incubation symptoms

Table 7: List of controllability reducing factors observed in Figs. 6 and 7 for COVID variants and generically parameterized diseases with incubation-latent offset $z = 1.5$ days.


3.2 Optimal allocation strategies

Figures 8 and 9 show the optimal resource allocation strategies ρ as a function of testing capacity C corresponding to the total infection size reductions in Figs. 6 and 7. Curve colors and styles are interpreted analogously according to the legend in Fig. 5. The value $\rho = 0$ represents a clinical-testing only strategy while $\rho = 1$ represents a non-clinical testing only strategy, with intermediate values represent mixed clinical and non-clinical testing strategies. In all cases, we find that optimal strategies call for clinical testing only at low testing capacities up to some strategy threshold capacity C^{th} , beyond which optimal strategies become mixed. As testing capacity increases further beyond C^{th} , optimal strategies call for greater and greater shares of resources to be devoted to non-clinical testing.


The insets in each plot (except Fig. 8d) zoom in on C^{th} values for the various distribution, symptom, testing parameter, and disease parameter assumptions. Figures 8 and 9 show that all of these factors except the non-clinical accessibility κ are important in determining C^{th} , while Fig. 8d indicates that C^{th} is in fact independent of κ . This observation can be explained from our model equations, where the total rate of flow of infected individuals to the quarantine class due to non-clinical testing is given by $\tau_N^{-1}\kappa X_N(t)$. At the threshold C^{th} , the optimal fraction of resources ρ devoted to nonclinical testing is only infinitesimally larger than zero, and Eq. (5) implies $\tau_N^{-1}\kappa X_N(t) \approx \rho CN X_N(t) / (X_N(t) + (1-\eta)(S(t) + U(t)))$ for very small ρ . We thus conclude that the rate at which individuals are quarantined by optimally allocated non-clinical testing is independent of κ at testing capacities near C^{th} , and that κ effectively vanishes from the model equations under optimal strategies at C^{th} .




(a) Original Variant: Variable Distribution and Symptom Assumptions



(b) Original Variant: Variable Distribution and Symptom Assumptions




(c) Original Variant: Gamma Distribution and Incubation Symptom Assumptions




(d) Original Variant: Gamma Distribution and Incubation Symptom Assumptions


Figure 8: Optimal resource allocation strategies for the original COVID variant corresponding to the total infection sizes in Fig. 6. The value $\rho = 0$ corresponds to clinical-testing only strategy, $\rho = 1$ corresponds to non-clinical testing only, with intermediate values representing mixed strategies. Insets within plots (aside from Fig. 8d) highlight strategy threshold testing capacity values C^{th} where strategies switch from clinical only to mixed. Note the changes in x-axis scale for each plot.




(a) Delta Variant: Variable Distribution and Symptom Assumptions



(b) Omicron Variant: Variable Distribution and Symptom Assumptions



(c) Generic Disease $R_0^{un} = 6.4$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions



(d) Generic Disease $R_0^{un} = 9.5$, $z = 1.5$ days: Variable Distribution and Symptom Assumptions

Figure 9: Optimal resource allocation strategies for the delta and omicron COVID variants as well as comparable generic diseases with a longer mean incubation period $\langle f_\varepsilon \rangle = 6.0$ days. Optimal strategies correspond to the optimal total infection sizes in Fig. 7. The value $\rho = 0$ corresponds to clinical-testing only strategy, $\rho = 1$ corresponds to non-clinical testing only, with intermediate values representing mixed strategies. Insets within plots highlight strategy threshold testing capacity values C^{th} where strategies switch from clinical only to mixed. Note the changes in x-axis scale for each plot.

468 3.3 Controllability and the role of non-clinical testing

469 Figures 6, 7, 8, and 9 together depict the relationship between controllability and the role of non-
470 clinical testing in optimal strategies. We say that the role of non-clinical testing is increased for set
471 ‘A’ of distribution, symptom onset, testing parameter, and disease parameter assumptions relative
472 to another set ‘B’ if the optimal ρ value at a given testing capacity for set ‘A’ is larger. Applying
473 the same comparative analyses to Figs. 8 and 9 as was done for Figs. 6 and 7 in Sec. 3.1, we
474 find that, except for the incubation symptoms assumption, all factors that reduce controllability
475 in Table 7 coincide with the factors that reduce the role of non-clinical testing. Thus there exists
476 a strong relationship between controllability influencing factors and the role of non-clinical testing
477 in optimal strategies.

478 The relationship between non-clinical testing and symptom onset assumptions is more nuanced
479 than for the other controllability reducing factors. Understanding this relationship is important
480 for disease control, as symptom onset assumptions either incorporate (incubation symptoms) or
481 disregard (correlated symptoms) the capacity for presymptomatic transmission associated with the
482 incubation-latent period offset for COVID-19. In some cases (compare gold to blue or purple to
483 orange curves in Figs. 8a and 8b), incubation symptoms decrease the role of non-clinical testing
484 relative to correlated symptoms, thus following the pattern of controllability reducing factors co-
485 inciding with non-clinical testing reducing factors. In other cases (Fig. 9), incubation symptoms
486 increases the role of non-clinical testing for a large range of testing capacities above the strategy
487 thresholds C^{th} even though controllability is reduced. Of further complication, in these cases, there
488 exist smaller ranges of larger testing capacities where the role of non-clinical testing is increased by
489 the incubation symptoms assumption.

490 We utilize strategy testing capacity thresholds C^{th} to analyze the relationship between non-
491 clinical testing and symptom onset assumptions. Specifically, in Figs. 8a and 8b, the reduced roles
492 of non-clinical testing under the incubation symptom assumptions correspond to larger C^{th} values
493 in comparison to the correlated symptoms assumptions. Likewise, in Fig. 9, the enhanced roles of
494 non-clinical testing over large ranges of testing capacities correspond to smaller C^{th} for incubation
495 symptoms in comparison to correlated symptoms. Thus, increases and decreases in C^{th} due to
496 symptom onset assumptions are simple indicators of decreases and increases, respectively, in the

497 roles of non-clinical testing. To further simplify our analysis, we restrict our attention to the most
498 realistic model assumptions using gamma distributions for f_ε and f_r to compare incubation symp-
499 toms (solid purple curves) to correlated symptoms (solid orange curves).

500 Numerically calculating C^{th} values for a spectrum of η values, we plot the results as curves in
501 the (C, η) plane, where different curves represent different variant and symptom onset assumptions
502 (Fig. 10). For a given variant, if the correlated symptom curve (orange) falls to the left of the
503 incubation symptom (purple) curve at a given η , then C^{th} is larger for incubation symptoms, thus
504 implying that incubation symptoms reduce the role of non-clinical testing. Conversely, if the cor-
505 related symptom curve falls to the right of the incubation symptoms curve, incubation symptoms
506 enhance the role of non-clinical testing. Further, for each variant, there exists a threshold concen-
507 tration η^{th} (indicated by black circles in Fig. 10), above which the role of non-clinical testing is
508 always enhanced, and below which it is always reduced, where threshold values decrease as variant
509 strength increases. Thus, whether or not the presence of presymptomatic transmission warrants
510 allocation of additional resources to non-clinical testing than would otherwise be optimal depends
511 on both variant strength and the precision to which non-clinical tests can locate infected individ-
512 uals: variants with greater infectiousness require less precision to justify additional resources for
513 non-clinical testing.

514 Figure 10 is of additional value as a practical result for disease management officials when
515 determining whether or not complicated resource allocation decisions need be considered. To see
516 this, suppose that the available testing capacity C and an estimate for the concentration η of a
517 non-clinical testing program are known. Then, if the corresponding (C, η) value falls to the left of
518 or below a variant curve in Fig. 10, the optimal strategy for that variant is clinical testing only, and
519 officials need not consider difficult choices in allocating resources. Otherwise, if the (C, η) value
520 falls to the right of or above a variant curve, the optimal strategy is mixed clinical and non-clinical
521 testing, and officials know that critical decisions must be made to ensure that resources are properly
522 allocated.




Figure 10: Strategy threshold testing capacities at various concentration levels η for the different COVID variants. Curves represent (C, η) values where the strategy threshold capacity C^{th} occurs, assuming either incubation symptoms (purple) or correlated symptoms (orange) with gamma distributed f_r and f_ε . At (C, η) points above or to the right of a given curve, optimal strategies are mixed clinical and non-clinical for that variant and symptom assumption. At points below or to the left, optimal strategies are clinical only. Circles indicate points where C^{th} is equivalent for both symptom assumptions. At η values above a circle, incubation symptoms increases the role of non-clinical testing in optimal strategies for the corresponding variant. At η values below a circle, incubation symptoms reduce the role of non-clinical testing.

523 3.4 Variable incubation-latent offsets

524 In Fig. 11, we plot optimal total infection sizes and corresponding optimal resource allocation
525 strategies for the generic disease with $R_0^{un} = 3.0$ under a variety of incubation-latent offsets z .
526 Here, we consider only gamma distributions for f_r and f_ε , and we consider both incubation and
527 correlated symptom assumptions (the offset z is irrelevant under correlated symptoms). The offset
528 z is found to have a strong influence on controllability (Figs. 11a and 11b); as z increases from neg-
529 ative to positive values, controllability decreases significantly. Thus, diseases for which symptom
530 onset typically occurs before peak infectiousness are more easily controlled with symptom-based
531 interventions compared to diseases for which symptom onset typically occurs after infectiousness
532 onset (i.e. presymptomatic transmission). Further, relative to the correlated symptoms assump-
533 tion, incubation symptoms are more controllable for $z < 0$ and less controllable for $z > 0$ (Figs. 11a
534 and 11b). This finding agrees with the notion that diseases for which symptoms precede signif-
535 icant infectiousness are easier to control; if a model disregards the offset between symptom and
536 infectiousness onset, it will underestimate controllability for diseases with $z < 0$ and overestimate
537 controllability for diseases with $z > 0$. Thus, Table 1 should be modified to state that incubation
538 symptoms are a controllability reducing factor only for diseases with $z > 0$, while correlated symp-
539 toms are a controllability reducing factor for $z < 0$. This expanded list of controllability reducing
540 factors is given in Table 8. For the case $z = 0$, controllability under incubation symptoms is close to
541 (but not exactly equal to) controllability under correlated symptoms (Figs. 11a and 11b). Appar-
542 ently, when symptom and infectiousness onset occur together only on average rather than always
543 together, controllability is very slightly reduced.


544 As a function of testing capacity, optimal strategies for all z behave qualitatively similar to
545 those of the COVID-19 variants; optimal strategies are clinical-only at low testing capacities and
546 become mixed clinical and non-clinical beyond a threshold capacity C^{th} (Figs. 11c and 11d). As
547 with the COVID-19 variants, the relationships between symptom onset assumptions, controllabil-
548 ity, and optimal allocation strategies are complicated for the generic disease. For random testing
549 (Fig. 11c), the role of non-clinical testing decreases (as measured by increases in C^{th}) as z increases
550 in the interval $[-4.5, 1.5]$, thus following the trend of controllability reducing factors coinciding with
551 non-clinical testing reducing factors. However, the role of non-clinical testing increases for $z = 4.5$

552 days relative to $z = 1.5$ days even though controllability decreases. For realistic testing (Fig. 11d),
553 the role of non-clinical testing decreases progressively as z increases in the interval $[-4.5, 0]$, after
554 which it progressively increases as z increases in $[0, 4.5]$. Of further complication, for larger R_0^{un}
555 values (see Supplementary Material Figs. S10 and S11), the role of non-clinical testing can increase
556 progressively as z increases despite the progressive decrease in controllability.


557 The role of non-clinical testing for incubation symptoms relative to that of correlated symp-
558 toms displays distinct behavior for $z < 0$ and $z \geq 0$. Specifically, for $z = -1.5$ days (green curve
559 in Figs. 11c and 11d), the role of non-clinical testing is enhanced relative to correlated symptoms
560 at $\eta = 0$, but is reduced at $\eta = 0.85$. This behavior is counterintuitive; one would expect that
561 if non-clinical testing is effective enough at low η to have an enhanced role in optimal strategies,
562 then it would also have an enhanced role at larger η , as increasing η would increase its efficacy
563 further. This is indeed the case for the COVID-19 variants that have a positive z approximately
564 equal to 1.50 days (Fig. 10). For these variants, the role of non-clinical testing becomes enhanced
565 relative to correlated symptoms at some threshold concentration η^{th} , and then remains enhanced
566 for all $\eta > \eta^{th}$. Figure 12 presents the analog to Fig. 10 for the generic disease for $R_0^{un} = 3.0$
567 (see Supplementary Material Figs. $R_0^{un} = 6.4$ and $R_0^{un} = 9.5$). Here, we numerically calculate
568 the strategy threshold capacities C^{th} for a spectrum of η values for each z offset and the corre-
569 lated symptoms assumptions, and then plot the results as curves in the (C, η) plane. For each z
570 curve, there is a threshold concentration η^{th} where a crossing with the correlated symptoms curve
571 occurs. $z \geq 0$ curves are to the right of the correlated symptoms curve for $\eta < \eta^{th}$ (indicating
572 diminished non-clinical testing roles) and to the left for $\eta > \eta^{th}$ (indicating enhanced non-clinical
573 testing roles). However, $z < 0$ curves are to the left of the correlated symptoms curve for $\eta < \eta^{th}$
574 (indicating enhanced non-clinical testing roles) and to the right for $\eta > \eta^{th}$ (indicating diminished
575 non-clinical testing roles). We thus find major qualitative differences between $z > 0$ diseases (i.e.
576 those with presymptomatic transmission) and $z < 0$ diseases (i.e those with symptom onset before
577 infectiousness) in regards to the influence of realistic incubation and latent periods on optimal re-
578 source allocation strategies relative to simpler models.

579 From Figs. 10 and 12 (as well as the corresponding Figs. S12 and S13 in the Supplementary
580 Material), it is clear that threshold concentrations η^{th} depend on both the incubation-latent offset
581 z and the overall transmissibility as measured by R_0^{un} , and may also depend on the mean latent


582 period length. To visualize these influences, we find the thresholds η^{th} numerically for the $z \leq 0$
583 diseases as well as the COVID-19 variants, assuming a spectrum of R_0^{un} values for each model by
584 changing the overall transmissibility. The results are plotted in Fig. 13 as curves in the (R_0^{un}, η)
585 plane, where each curve represents η^{th} values for a different set of gamma distributed latent and
586 incubation periods taken from Tables 2, 3, 4, and 6, assuming gamma distributions for f_r . If a
587 disease management official is designing a testing resource allocation strategy to control a disease
588 for which they know the basic reproduction number and an estimate for their testing program's
589 η reproduction, they can locate the corresponding point in Fig. 13. If their point falls above the
590 relevant incubation/latent period assumption curve, then due to presymptomatic transmission, op-
591 timal strategies will call for an increase in non-clinical testing resources relative to a comparable
592 simpler disease for which infectiousness and symptoms always coincide. If their point falls below the
593 relevant incubation/latent period assumption curve, optimal strategies will call for a reduction in
594 non-clinical testing relative to a comparable simpler disease despite the presence of presymptomatic
595 transmission. Generally, smaller R_0^{un} values require greater η to justify allocating extra resources
596 to non-clinical testing, thus corroborating our previous observation that diseases with greater in-
597 fectiousness require less precise non-clinical testing programs (i.e smaller η) to justify allocating
598 additional resources to non-clinical testing due to presymptomatic transmission. We see further
599 that larger z diseases and diseases with shorter latent periods (compare the omicron curve to the
600 $z = 1.50$ curve) likewise require less precision to justify increasing resources to non-clinical testing.
601 In other words, the factors of larger R_0^{un} , larger z , and smaller latent period expand the parameter
602 space for which non-clinical testing is enhanced in optimal strategies due to presymptomatic trans-
603 mission. Note that as R_0^{un} falls below 2.0, enhanced non-clinical testing is never justified. Thus,
604 diseases with sufficiently low infectiousness do not warrant additional non-clinical testing resources,
605 even if presymptomatic transmission may be significant.




(a) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(b) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(c) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets



(d) Generic Disease $R_0^{un} = 3.0$: Gamma Distribution Assumptions and Variable Incubation-Latent Offsets

Figure 11: Optimal total infection sizes and corresponding optimal resource allocation strategies for the generic disease with $R_0^{un} = 3.0$, assuming gamma distributions for f_ϵ and f_r . Curve colors represent different offsets $z = \langle f_I \rangle - \langle f_\epsilon \rangle$ between mean incubation and latent periods as indicated by the legend in Fig. 11a (measured in units of days). Black dashed curves represent the correlated symptoms assumption where z values are irrelevant. Insets in Figs. 11c and 11d zoom in on strategy threshold testing capacities C^{th} where optimal strategies switch from clinical only to mixed clinical and non-clinical.

Controllability reducing factors
f_r gamma distribution
f_ε exponential distribution
reduction in non-clinical concentration η
reduction in non-clinical accessibility κ
increase in overall transmissibility (i.e. R_0^{un})
reduction in mean latent period $\langle f_\varepsilon \rangle$
incubation symptoms when $z > 0$
correlated symptoms when $z < 0$

Table 8: Expanded list of controllability reducing factors for both $z > 0$ and $z < 0$ diseases as observed in Figs. 6, 7, and 11.




Figure 12: Strategy threshold testing capacities at various concentration levels η for the generic disease with $R_0^{un} = 3.0$. Curves represent (C, η) values where the strategy threshold capacity C^{th} occurs, assuming either incubation symptoms (colored curves) or correlated symptoms (black dashed curve) with gamma distributed f_r and f_ε . Colors represents different off sets z between the mean incubation and mean latent period, with values in the legend given in units of days. At (C, η) points above or to the right of a given curve, optimal strategies are mixed clinical and non-clinical for that z value or symptom assumption. At points below or to the left, optimal strategies are clinical only. The η value for which a colored curve crosses the black curve represents a threshold η^{th} for which the role of non-clinical testing switches between enhanced and diminished compared to the correlated symptoms assumption.




Figure 13: Curves depicting threshold concentrations η^{th} as a function of the uncontrolled basic reproduction number for gamma distributed latent and incubation period associated with the COVID-19 variants and our generic diseases, where f_r is assumed to be gamma distributed. Each curve represents a different latent/incubation period set that has a particular incubation-latent offset z denoted in the legend in units of days. The legend specifies the COVID variants along with their z offsets, and the generic disease indicated by only their z offsets. The actual R_0^{un} values for the COVID variants are indicated by markers on the plot. Points above a given curve represent the parameter space over which presymptomatic transmission justifies increasing resources to non-clinical testing for a disease with the corresponding latent and incubation periods. For points below a curve, presymptomatic transmission does not justify increasing non-clinical testing resources in optimal strategies.

606 4 Discussion

607 4.1 Curbing epidemics under resource limitations

608 The results of our work build a robust mathematical justification for the optimality of the test-
609 ing strategies adopted by real-world disease management planners during the early phases of the
610 COVID-19 pandemic. Namely, when testing resources are in short supply, they should be reserved
611 for the most symptomatic and critically ill patients (6, 7, 8). Although these policies may have
612 been adopted to prevent mortality, we have found that they are also good policies for suppressing
613 an epidemic. More generally, our work shows that such policies are optimal for a broad range
614 of disease characteristics and non-clinical testing program characteristics. Diseases with longer or
615 shorter latent periods, stronger or weaker transmissibility, presymptomatic transmission or symp-
616 tom onset before infectiousness or correlated symptom-infectiousness onset, and exponential or
617 gamma period distributions all call for qualitatively similar policies as a function of testing ca-
618 pacity; optimal protocols call for clinical-only testing at testing capacities below a threshold C^{th} ,
619 and call for mixed clinical and non-clinical strategies at greater testing capacities. Interestingly,
620 in a previous work (18) where we analyzed optimally reducing the epidemic peak height (rather
621 than total infection size) using the reduced and simplified ODE counterpart of our model here, we
622 observed the same threshold behavior separating testing capacity regions between optimal clinical-
623 only and mixed strategies. Thus, the threshold behavior appears to be a general feature of optimal
624 allocation strategies under limited testing resources.

625 Figures 6, 7, and 11 depicting optimal total infection size for “realistic” and “random” non-
626 clinical testing programs illuminate the feasibility or infeasibility of curbing a novel disease outbreak
627 with a testing and quarantine program. Random testing ($\eta = 0$) is unlikely to be successful at the
628 low testing capacities expected at the initial stages of a novel disease outbreak as production of
629 newly developed tests falls well behind demand, even if the entire population is accessible and
630 amenable to the limited number of tests available ($\kappa = 1$). However, significant disease suppression
631 is possible at larger concentrations η even if the overall accessibility κ is small. This result stresses
632 the importance of early implementation of effective contact tracing and public outreach programs
633 encouraging individuals with suspected or probable recent transmission to seek testing, even if
634 significant portions of the population are not open or accessible to such efforts. Importantly, this

635 conclusion holds for the spectrum of model assumptions and disease characteristics analyzed in this
636 paper.

637 4.2 Influence of model assumptions on controllability

638 Throughout this work, we have identified a number of disease characteristics and model assumptions
639 that influence predictions of controllability. Model assumptions regarding latent period, incubation
640 period, and recovery day distributions as well as incubation-latent offsets are critically important,
641 as we have found that the exponential distribution and correlated symptom assumptions in the
642 equivalent ODE model can severely overestimate controllability relative to the full IPDE model
643 for the COVID-19 variants. The gamma distribution assumptions for f_ϵ , f_I , and f_r used in the
644 full IPDE model are supported by epidemiological data and are far more realistic than ODE as-
645 sumptions, so the reduced controllability exhibited by our model is a closer reflection of reality.
646 Our model's ability to decouple symptom onset from disease compartments plays a key role in its
647 capacity to simultaneously incorporate realistic latent and incubation period distributions.

648 A major contributing factor to reduced controllability in the full IPDE model is the gamma
649 period distribution for f_r . This observation accords with previous models with identification + isola-
650 tion/quarantine controls, where it was observed that an exponentially distributed infectious period
651 can significantly overestimate controllability relative to a gamma distribution (27). In essence,
652 quarantining is more effective under the exponential assumption due to its ability to significantly
653 reduce the infectious period length of individuals in the long tail of the distribution (see Fig. 3).
654 Likewise, under the exponential assumption, significantly larger numbers individuals recover nat-
655 urally within the first few days of infectiousness onset in comparison to the gamma assumption,
656 so delays in testing due to low capacity are irrelevant in these cases and are thus less detrimental
657 to controllability. Conversely, for the latent period distribution, a gamma distribution assumption
658 increases controllability relative to the exponential assumption (although to a lesser degree than
659 that with which a gamma f_r reduces controllability) for reasons analogous to those of infectious
660 period. Namely, under the exponential assumption, much larger numbers of individuals rapidly
661 transition from exposed to infectious in comparison to the gamma distribution, so there is less time
662 to locate and remove new infections before they begin generating new transmissions, and delays in
663 identifying and quarantining infections due to supply limitations are thus more detrimental. On a

664 more basic level, although gamma distributions for f_ε and f_r have no noticeable effect on total in-
665 fection size under no control, they flatten/delay and sharpen/accelerate the uncontrolled epidemic
666 peak, respectively, as compared to exponential distributions (see the Supplementary Material sec-
667 tion S3). Intuitively, a disease that peaks earlier and to a greater degree on its on volition will be
668 more difficult to control.

669 Symptom onset assumptions based on the age-of-infection can reduce or increase controllability
670 depending on the incubation-latent offset z , as controllability generally decreases as z increases.
671 Under correlated symptoms, active spreaders in the ES class always show symptoms and are thus
672 always targeted with efficacious clinical testing. Under incubation symptoms, however, positive z
673 values imply presymptomatic transmissions, meaning that some of the active spreaders can only
674 be targeted with non-clinical testing which is subject to delays due to resources being wasted on
675 uninfected individuals. These delays become more detrimental as the presymptomatic transmission
676 window becomes larger, so controllability tends to decrease as z increases. For negative z , however,
677 some individuals become symptomatic while still in the exposed class, so efficacious clinical testing
678 can be used to remove infected individuals with minimal delay before they can begin generating
679 new transmissions. This is impossible under correlated symptoms or positive z values. The oppor-
680 tunity for clinical testing to remove preinfectious individuals increases as z grows in the negative
681 direction, and controllability consequently increases. Notably, the increase in controllability can be
682 significant for a negative z disease compared to a positive z disease. This observation may explain
683 why the 2003 SARS outbreak (negative z disease) was far easier to control than the COVID-19
684 pandemic (positive z disease) (54).

685 The remaining controllability reducing factors are straightforwardly explained. Namely, a more
686 transmissible disease (i.e. one with a larger R_0^{un}) is inherently more difficult to control than a less
687 transmissible disease, and the larger number of secondary infections generated by an individual can
688 be detrimental to control when limited resources force delays in testing and quarantine. Likewise,
689 shorter latent periods leave less time to locate infected individuals before they begin generating
690 transmissions, so testing and quarantine delays become more costly. These factors together help
691 explain why the omicron variant has been particularly challenging to control (49, 55). The large
692 R_0^{un} value is an oft emphasized contributing factor, but the short latent period relative to other
693 variants can be just as important. Explicitly, comparing the generic disease (mean latent period 6

694 days) to the omicron variant (mean latent period 1.5 days) in Fig. 7 shows that omicron is roughly
695 half as controllable despite both diseases having the same R_0^{un} .

696 4.3 Controllability, symptom onset, and the role of non-clinical testing

697 Our results across all model assumptions demonstrate a consistent clear relationship between non-
698 clinical testing and controllability reducing factors unrelated to symptom onset assumptions: factors
699 that reduce controllability also reduce the role of non-clinical testing in optimal strategies. We hy-
700 pothesize that this relationship arises because wasted or inefficiently used resources are of greater
701 detriment in a less controllable system. That is, when a disease is considered less controllable, fail-
702 ure to utilize a quantity of testing capacity to identify and isolate infected individuals will result in
703 a greater number of additional infections in comparison to a more controllable disease. With non-
704 clinical testing, the beneficial impact of identifying removing non-symptomatic infected individuals
705 is counterbalanced by the negative impact of potentially wasting tests on uninfected individuals,
706 and the negative impact becomes more prominent as the disease becomes less controllable. Thus,
707 optimal strategies place more emphasis on clinical testing which is guaranteed to be utilized to iden-
708 tify and isolate an infected individual. However, for sufficiently large testing capacity, resources are
709 plentiful enough such that wasting a test on an uninfected individual does not significantly delay or
710 inhibit identification of infected individuals, so the role of non-clinical testing can be prominent in
711 a less controllable disease, although still slightly diminished in comparison to a more controllable
712 disease. Thus, the observed relationship between the role of non-clinical testing and controllability
713 is closely tied to the resource limitation aspects of model.

714 In contrast to factors unrelated to symptom onset, the relationship symptom onset assumptions
715 and non-clinical testing is unclear. On one hand, one might expect that for a negative z disease like
716 COVID-19, realistically modeling the incubation-latent offset will increase the role of non-clinical
717 testing in comparison to a model making the simpler correlated symptom assumption due to the
718 ability of non-clinical testing to capture presymptomatic spreaders. On the other hand, since the
719 latent incubation offset decreases controllability for a negative z disease, one might expect the role
720 of non-clinical testing to be diminished due to the reasoning given in the preceding paragraph. We
721 found that neither of these hypotheses are generally correct for guiding optimal strategies based
722 on the results of simple ODE models. Instead, we found that age-of-infection modeling, and in

723 particular, the details of the temporal offset between the incubation and latent periods, was critical
724 to understanding disease progression, controllability, and optimal strategies for resource allocation.

725 Our results show that optimal policies for resource allocation depend on a complicated (often
726 non-intuitive) interplay between incubation-latent offset, disease strength, and other characteris-
727 tics like latent period length (Figs. 11, 12, 13 and the corresponding Figs. S10, S11, S12, S13 in
728 the Supplementary Material). This is a critical observation because real-world public policies and
729 attitudes towards a novel diseases are typically based on what has been successful for previous
730 diseases combined with basic intuition for the broad differences between the novel disease and pre-
731 vious diseases. For example, 2003 SARS has no presymptomatic transmission while COVID-19 has
732 significant presymptomatic transmission, so one might intuitively expect that a successful strat-
733 egy for controlling 2003 SARS should be adapted for COVID-19 by allocating more resources to
734 non-clinical testing to capture presymptomatic spreaders, but this is not at all the case accord-
735 ing to our results. Our work shows that this intuition-based approach to public policy can fail,
736 and thus highlights the importance of mathematical modeling in helping to guide disease man-
737 agement. In particular, it is important to establish modeling frameworks where different diseases
738 can be examined comparatively under the same lens to more closely mimic the way diseases are
739 compared in the real world. Utilizing the age-of-infection to decouple symptom status from specific
740 model compartments is the crucial element for allowing such comparisons in our model. Future
741 models may build upon these ideas to incorporate not only the age-of-infection, but also the age-
742 of-infectiousness to model additional realistic features like partial correlations between incubation,
743 latent, and infectious period lengths as well as time-varying infectivity levels dependent on the time
744 since infectiousness or symptom onset.

745 **Acknowledgments**

746 This work was funded by the Center of Advanced Systems Understanding (CASUS) which is fi-
747 nanced by Germanys Federal Ministry of Education and Research (BMBF) and by the Saxon
748 Ministry for Science, Culture and Tourism (SMWK) with tax funds on the basis of the budget
749 approved by the Saxon State Parliament.

750 References

- 751 [1] World Health Organization. WHO Director-General’s opening remarks at the media
752 briefing on COVID-19 - 11 March 2020, 2020. [cited 2022 October 24]. Available
753 from: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020>.
754
- 755 [2] World Health Organization. WHO COVID-19 Dashboard, 2020. [cited 2022 October 24].
756 Available from: <https://covid19.who.int/>.
- 757 [3] Antoine Mandel and Vipin Veetil. The economic cost of COVID I Lockdowns: An out-
758 of-eEquilibrium analysis. *Econ Disaster Clim Chang*, 4:431–451, 2020. doi: 10.1007/
759 s41885-020-00066-z.
- 760 [4] Adam Rose. COVID-19 economic impacts in perspective: A comparison to recent U.S. disas-
761 ters. *Int J Disaster Risk Reduct*, 60:102317, June 2021. doi: 10.1016/j.ijdr.2021.102317.
- 762 [5] Eva Clark, Elizabeth Y Chiao, and E Susan Amirian. Why contact tracing efforts have failed
763 to curb coronavirus disease 2019 (COVID-19) transmission in much of the United States. *Clin*
764 *Infect Dis*, 72:e415–e419, 2021. doi: 10.1093/cid/ciaa1155.
- 765 [6] E. Susan Amirian. Prioritizing COVID-19 test utilization during supply shortages in the late
766 phase pandemic. *J Public Health Policy*, 43:320–324, 2022. doi: 10.1057/s41271-022-00348-8.
- 767 [7] Centers for Disease Control and Prevention. Investigating a COVID-19 case, 2022. [cited
768 2022 October 24]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/investigating-covid-19-case.html>.
769
- 770 [8] World Health Organization. Public health surveillance for COVID-19: Interim guidance, 2022.
771 [cited 2022 October 24]. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-SurveillanceGuidance-2022.2>.
772
- 773 [9] William V. Padula. Why only test symptomatic patients? Consider random screen-
774 ing for COVID-19. *Appl Health Econ Health Policy*, 18:333–334, 2020. doi: 10.1007/
775 s40258-020-00579-4.

- 776 [10] Hualei Xin, Yu Li, Peng Wu, Zhili Li, Eric H Y Lau, Ying Qin, Liping Wang, Benjamin J
777 Cowling, Tim K Tsang, and Zhongjie Li. Estimating the latent period of coronavirus disease
778 2019 (COVID-19). *Clin Infect Dis*, 74:1678–1681, 2022. doi: 10.1093/cid/ciab746.
- 779 [11] Min Kang, Hualei Xin, Jun Yuan, Sheikh Taslim Ali, Zimian Liang, Jiayi Zhang, Ting
780 Hu, Eric HY Lau, Yingtao Zhang, Meng Zhang, Benjamin J Cowling, Yan Li, and Peng
781 Wu. Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta vari-
782 ant infections in Guangdong, China, May to June 2021. *Eurosurveillance*, 27, 2022. doi:
783 10.2807/1560-7917.ES.2022.27.10.2100815.
- 784 [12] Nathan W. Furukawa, John T. Brooks, and Jeremy Sobel. Evidence supporting transmission
785 of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic.
786 *Emerg Infect Dis*, 26:e201595, 2020. doi: 10.3201/eid2607.201595.
- 787 [13] Kieran A. Walsh, Karen Jordan, Barbara Clyne, Daniela Rohde, Linda Drummond, Paula
788 Byrne, Susan Ahern, Paul G. Carty, Kirsty K. O’Brien, Eamon O’Murchu, Michelle O’Neill,
789 Susan M. Smith, Mirn Ryan, and Patricia Harrington. SARS-CoV-2 detection, viral load and
790 infectivity over the course of an infection. *J Infect*, 81:357–371, 2020. doi: 10.1016/j.jinf.2020.
791 06.067.
- 792 [14] Arabella Widders, Alex Broom, and Jennifer Broom. SARS-CoV-2: The viral shedding vs
793 infectivity dilemma. *Infect Dis Health*, 25:210–215, 2020. doi: 10.1016/j.idh.2020.05.002.
- 794 [15] Qiuyue Ma, Jue Liu, Qiao Liu, Liangyu Kang, Runqing Liu, Wenzhan Jing, Yu Wu, and Min
795 Liu. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population
796 and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysis.
797 *JAMA Netw Open*, 4:e2137257, 2021. doi: 10.1001/jamanetworkopen.2021.37257.
- 798 [16] Amin Yousefpour, Hadi Jahanshahi, and Stelios Bekiros. Optimal policies for control of the
799 novel coronavirus disease (COVID-19) outbreak. *Chaos Solitons Fractals*, 136:109883, 2020.
800 doi: 10.1016/j.chaos.2020.109883.
- 801 [17] Lautaro Vassallo, Ignacio A. Perez, Lucila G. Alvarez-Zuzek, Julin Amaya, Marcos F. Torres,
802 Lucas D. Valdez, Cristian E. La Rocca, and Lidia A. Braunstein. An epidemic model for

- 803 COVID-19 transmission in Argentina: Exploration of the alternating quarantine and massive
804 testing strategies. *Math Biosci*, 346:108664, 2022. doi: 10.1016/j.mbs.2021.108664.
- 805 [18] Justin M. Calabrese and Jeffery Demers. How optimal allocation of limited testing capacity
806 changes epidemic dynamics. *J Theor Biol*, 538:111017, 2022. doi: 10.1016/j.jtbi.2022.1110173.
- 807 [19] Alberto Olivares and Ernesto Staffetti. Optimal control-based vaccination and testing
808 strategies for COVID-19. *Comput Methods Programs Biomed*, 211:106411, 2021. doi:
809 10.1016/j.cmpb.2021.106411.
- 810 [20] Steffen E. Eikenberry, Marina Mancuso, Enahoro Iboi, Tin Phan, Keenan Eikenberry, Yang
811 Kuang, Eric Kostelich, and Abba B. Gumel. To mask or not to mask: Modeling the potential
812 for face mask use by the general public to curtail the COVID-19 pandemic. *Infect Dis Model*,
813 5:293–308, 2020. doi: 10.1016/j.idm.2020.04.001.
- 814 [21] Kristina P. Vatcheva, Josef Sifuentes, Tamer Oraby, Jose Campo Maldonado, Timothy Huber,
815 and Mara Cristina Villalobos. Social distancing and testing as optimal strategies against the
816 spread of COVID-19 in the Rio Grande Valley of Texas. *Infect Dis Model*, 6:729–742, 2021.
817 doi: 10.1016/j.idm.2021.04.004.
- 818 [22] Calistus N. Ngonghala, Enahoro A. Iboi, and Abba B. Gumel. Could masks curtail the post-
819 lockdown resurgence of COVID-19 in the US? *Mathl Biosci*, 329:108452, 2020. doi: 10.1016/
820 j.mbs.2020.108452.
- 821 [23] Colin J. Worby and Hsiao-Han Chang. Face mask use in the general population and optimal
822 resource allocation during the COVID-19 pandemic. *Nat Commun*, 11:4049, 2020. doi: 10.
823 1038/s41467-020-17922-x.
- 824 [24] Sarah F. Poole, Jessica Gronsbell, Dale Winter, Stefanie Nickels, Roie Levy, Bin Fu, Maximilien
825 Burq, Sohrab Saeb, Matthew D. Edwards, Michael K. Behr, Vignesh Kumaresan, Alexander R.
826 Macalalad, Sneha Shah, Michelle Prevost, Nigel Snoad, Michael P. Brenner, Lance J. Myers,
827 Paul Varghese, Robert M. Califf, Vindell Washington, Vivian S. Lee, and Menachem Fromer.
828 A holistic approach for suppression of COVID-19 spread in workplaces and universities. *PLoS*
829 *One*, 16:e0254798, 2021. doi: 10.1371/journal.pone.0254798.

- 830 [25] Joshua Kiddy K. Asamoah, Zhen Jin, Gui-Quan Sun, Baba Seidu, Ernest Yankson, Afeez
831 Abidemi, F.T. Oduro, Stephen E. Moore, and Eric Okyere. Sensitivity assessment and op-
832 timal economic evaluation of a new COVID-19 compartmental epidemic model with control
833 interventions. *Chaos Soliton Fractal*, 146:110885, 2021. doi: 10.1016/j.chaos.2021.110885.
- 834 [26] Paul J. Hurtado and Adam S. Kiro Singh. Generalizations of the Linear Chain Trick: incorpo-
835 rating more flexible dwell time distributions into mean field ODE models. *J Math Biol*, 79(5):
836 1831–1883, 2019. doi: 10.1007/s00285-019-01412-w.
- 837 [27] Helen J Wearing, Pejman Rohani, and Matt J Keeling. Appropriate models for the manage-
838 ment of infectious diseases. *PLoS Med*, 2:e174, 2005. doi: 10.1371/journal.pmed.0020174.
- 839 [28] Zhonglan Wu, David Harrich, Zhongyang Li, Dongsheng Hu, and Dongsheng Li. The unique
840 features of SARSCoV2 transmission: Comparison with SARSCoV, MERSCoV and 2009 H1N1
841 pandemic influenza virus. *Rev Med Virol*, 31:e2171, 2021. doi: 10.1002/rmv.2171.
- 842 [29] Guang Zeng, Shu-Yun Xie, Qin Li, and Jian-Ming Ou. Infectivity of severe acute respiratory
843 syndrome during its incubation period. *Biomed Environ Sci*, 22:502–510, 2009. doi: 10.1016/
844 S0895-3988(10)60008-6.
- 845 [30] Andrew William Byrne, David McEvoy, Aine B Collins, Kevin Hunt, Miriam Casey, Ann Bar-
846 ber, Francis Butler, John Griffin, Elizabeth A Lane, Conor McAloon, Kirsty O’Brien, Patrick
847 Wall, Kieran A Walsh, and Simon J More. Inferred duration of infectious period of SARS-CoV-
848 2: Rapid scoping review and analysis of available evidence for asymptomatic and symptomatic
849 COVID-19 cases. *BMJ Open*, 10:e039856, 2020. doi: 10.1136/bmjopen-2020-039856.
- 850 [31] Muge Cevik, Matthew Tate, Ollie Lloyd, Alberto Enrico Maraolo, Jenna Schafers, and Antonia
851 Ho. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shed-
852 ding, and infectiousness: A systematic review and meta-analysis. *Lancet Microbe*, 2:e13–e22,
853 2021. doi: 10.1016/S2666-5247(20)30172-5.
- 854 [32] Jantien A Backer, Don Klinkenberg, and Jacco Wallinga. Incubation period of 2019 novel
855 coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 28 January 2020.
856 *Eurosurveillance*, 25, 2020. doi: 10.2807/1560-7917.ES.2020.25.5.2000062.

- 857 [33] Stephen A. Lauer, Kyra H. Grantz, Qifang Bi, Forrest K. Jones, Qulu Zheng, Hannah R.
858 Meredith, Andrew S. Azman, Nicholas G. Reich, and Justin Lessler. The incubation period
859 of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation
860 and application. *Ann Intern Med*, 172:577–582, 2020. doi: 10.7326/M20-0504.
- 861 [34] Qun Li, Xuhua Guan, Peng Wu, Xiaoye Wang, Lei Zhou, Yeqing Tong, Ruiqi Ren, Kathy S.M.
862 Leung, Eric H.Y. Lau, Jessica Y. Wong, Xuesen Xing, Nijuan Xiang, Yang Wu, Chao Li,
863 Qi Chen, Dan Li, Tian Liu, Jing Zhao, Man Liu, Wenxiao Tu, Chuding Chen, Lianmei Jin,
864 Rui Yang, Qi Wang, Suhua Zhou, Rui Wang, Hui Liu, Yinbo Luo, Yuan Liu, Ge Shao, Huan Li,
865 Zhongfa Tao, Yang Yang, Zhiqiang Deng, Boxi Liu, Zhitao Ma, Yanping Zhang, Guoqing Shi,
866 Tommy T.Y. Lam, Joseph T. Wu, George F. Gao, Benjamin J. Cowling, Bo Yang, Gabriel M.
867 Leung, and Zijian Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-
868 infected pneumonia. *N Engl J Med*, 382:1199–1207, 2020. doi: 10.1056/NEJMoa2001316.
- 869 [35] Conor McAloon, ine Collins, Kevin Hunt, Ann Barber, Andrew W Byrne, Francis Butler,
870 Miriam Casey, John Griffin, Elizabeth Lane, David McEvoy, Patrick Wall, Martin Green,
871 Luke O’Grady, and Simon J More. Incubation period of COVID-19: A rapid systematic
872 review and meta-analysis of observational research. *BMJ Open*, 10:e039652, 2020. doi: 10.
873 1136/bmjopen-2020-039652.
- 874 [36] Balram Rai, Anandi Shukla, and Laxmi Kant Dwivedi. Incubation period for COVID-19: A
875 systematic review and meta-analysis. *J Public Health*, 2021. doi: 10.1007/s10389-021-01478-1.
- 876 [37] Hualei Xin, Jessica Y Wong, Caitriona Murphy, Amy Yeung, Sheikh Taslim Ali, Peng Wu,
877 and Benjamin J Cowling. The incubation period distribution of coronavirus disease 2019: A
878 systematic review and meta-analysis. *Clin Infect Dis*, 73:2344–2352, December 2021. doi:
879 10.1093/cid/ciab501.
- 880 [38] Hideo Tanaka, Tsuyoshi Ogata, Toshiyuki Shibata, Hitomi Nagai, Yuki Takahashi, Masaru
881 Kinoshita, Keisuke Matsubayashi, Sanae Hattori, and Chie Taniguchi. Shorter incubation
882 period among COVID-19 cases with the BA.1 Omicron variant. *Int J Environ Res Public*
883 *Health*, 19:6330, 2022. doi: 10.3390/ijerph19106330.

- 884 [39] Lauren Jansen. Investigation of a SARS-CoV-2 B.1.1.529 (omicron) variant cluster Nebraska,
885 NovemberDecember 2021. *MMWR. Morbidity and Mortality Weekly Report*, 70, 2021. doi:
886 10.15585/mmwr.mm705152e3.
- 887 [40] Javier Del guila Meja, Reinhard Wallmann, Jorge Calvo-Montes, Jess Rodriguez-Lozano,
888 Trinidad Valle-Madrado, and Adrian Aginagalde-Llorente. Secondary attack rate, transmission
889 and incubation periods, and serial interval of SARS-CoV-2 Omicron variant, Spain. *Emerg*
890 *Infect Dis*, 28:1224–1228, 2022. doi: 10.3201/eid2806.220158.
- 891 [41] Mina Park, Colleen Pawliuk, Tribesty Nguyen, Amanda Griffitt, Linda Dix-Cooper, Nadia
892 Fourik, and Martin Dawes. Determining the communicable period of SARS-CoV-2: A rapid
893 review of the literature, March to September 2020. *Euro Surveil*, 26, 2021. doi: 10.2807/
894 1560-7917.ES.2021.26.14.2001506.
- 895 [42] Yang Liu, Li-Meng Yan, Lagen Wan, Tian-Xin Xiang, Aiping Le, Jia-Ming Liu, Malik Peiris,
896 Leo L M Poon, and Wei Zhang. Viral dynamics in mild and severe cases of COVID-19. *Lancet*
897 *Infect Dis*, 20:656–657, 2020. ISSN 14733099. doi: 10.1016/S1473-3099(20)30232-2.
- 898 [43] A. Maisa, G. Spaccaferri, L. Fournier, J. Schaeffer, J. Deniau, P. Rolland, B. Coignard, A. An-
899 drieru, O. Broustal, S. Chene, S. Chent, E. Fougere, G. Gbaguidi, M. Hamidouche, A. Lamy,
900 Q. Mano, B. Mastrovito, A. Mercier, G. Modenesi, G. Picard, J. Prudhomme, F. Rappilly,
901 A. Riondel, M. Rivire, B. Villegas Ramirez, A. Zhu-Soubise, M. Zurbaran, A. Amzert, L. An-
902 dreoletti, A. Bal, R. Beaurepere, S. Behillil, L. Belec, C. Bernard, L. Bocket, L. Bouri,
903 T. Bourlet, C. Bressollette-Bodin, S. Brichler, C. Brugerolles, S. Cado, V. Calvez, N. Capron,
904 S. Castelain, J. Castro-Alvarez, M.-L. Chaix, C. Charpentier, D. Che, C. Chillou, P. Colson,
905 P. Coudene, A. Crinquette, A. De Rougemont, H. Delagrverie, C. Delamare, T. Denecker-
906 Berardino, D. Descamps, M. Desroches, G. Destras, G. Dos Santos, A. Ducancelle, S. Ducreux,
907 T. Duret, V. Enouf, S. Fafi-Kremer, C. Felici, S. Fourati, P.-E. Fournier, C. Gaudy, H. Ger-
908 main, V. Giordanengo, O. Gorge, S. Haim-Boukobza, C. Henquell, A. Holstein, L. Houhamdi,
909 J. Izopet, V. Giacomo, A. Jacques, M.-C. Jaffar-Bandjee, M. Jimenez, L. Josset, S. Kemeny,
910 M.-E. Lafon, A. Le Bars, G. Le Corguille, Q. Lepiller, A. Levasseur, N. Leveque, B. Lina,
911 C. Madelaine, C. Malabat, S. Marque-Juillet, T. Martin-Dunavit, P. Mavingui, A. Merens,

- 912 I. Messak, L. Morand-Joubert, X. Naudot, P. Neybecker, J.-M. Pawlotsky, L. Pilorge, J.-C.
913 Plantier, C. Poggi, M. Pretet, C. Ragot, H. Raoul, S. Rogez, A.-M. Roque-Afonso, B. Roque-
914 bert, D. Rousset, F. Rozenberg, C. Sagot, S. Sahnoune, D. Salgado, O. Sand, C. Saudemont,
915 E. Schvoerer, E. Simon-Loriere, R. Stephan, J. Sudour, V. Thibault, E. Tuailon, A. Vabret,
916 E. Vallee, S. Van Der Werf, J. Van Helden, L. Verdurme, A. Vignola, D. Wilkinson, and
917 Y. Yazdanpanah. First cases of Omicron in France are exhibiting mild symptoms, November
918 2021January 2022. *Infect Dis Now*, 52:160–164, 2022. doi: 10.1016/j.idnow.2022.02.003.
- 919 [44] Andrew A Sayampanathan, Cheryl S Heng, Phua Hwee Pin, Junxiong Pang, Teoh Yee Leong,
920 and Vernon J Lee. Infectivity of asymptomatic versus symptomatic COVID-19. *Lancet*, 397:
921 93–94, 2021. doi: 10.1016/S0140-6736(20)32651-9.
- 922 [45] Maimuna S Majumder and Kenneth D Mandl. Early in the epidemic: impact of preprints on
923 global discourse about COVID-19 transmissibility. *Lancet Glob Health*, 8:e627–e630, 2020. doi:
924 10.1016/S2214-109X(20)30113-3.
- 925 [46] Ral Patricio Fernandez-Naranjo, Eduardo Vsconez-Gonzlez, Katherine Simbaa-Rivera, Lenin
926 Gmez-Barreno, Juan S. Izquierdo-Condoy, Domnica Cevallos-Robalino, and Esteban Ortiz-
927 Prado. Statistical data driven approach of COVID-19 in Ecuador: R0 and Rt estimation via
928 new method. *Infect Dis Model*, 6:232–243, 2021. doi: 10.1016/j.idm.2020.12.012.
- 929 [47] Cheng-Jun Yu, Zi-Xiao Wang, Yue Xu, Ming-Xia Hu, Kai Chen, and Gang Qin. Assessment
930 of basic reproductive number for COVID-19 at global level: A meta-analysis. *Medicine*, 100:
931 e25837, 2021. doi: 10.1097/MD.0000000000025837.
- 932 [48] Ying Liu and Joacim Rocklöv. The reproductive number of the Delta variant of SARS-CoV-2
933 is far higher compared to the ancestral SARS-CoV-2 virus. *J Travel Med*, 28:taab124, 2021.
934 doi: 10.1093/jtm/taab124.
- 935 [49] Talha Khan Burki. Omicron variant and booster COVID-19 vaccines. *Lancet Respir Med*, 10:
936 e17, 2022. doi: 10.1016/S2213-2600(21)00559-2.
- 937 [50] Ying Liu and Joacim Rocklöv. The effective reproductive number of the Omicron variant

938 of SARS-CoV-2 is several times relative to Delta. *J Travel Med*, 29:taac037, 2022. doi:
939 10.1093/jtm/taac037.

940 [51] Yoshiaki Gu, Nobuhiro Komiya, Hajime Kamiya, Yoshinori Yasui, Kiyosu Taniguchi, and
941 Nobuhiko Okabe. Pandemic (H1N1) 2009 transmission during presymptomatic phase, Japan.
942 *Emerg Infect Dis*, 17:1737–1739, 2011. doi: 10.3201/eid1709.101411.

943 [52] F. T. M. Freitas, A. P. S. Cabral, E. N. C. Barros, M. J. O. Burigo, R. D. Prochnow, L. A.
944 Silva, M. A. Widdowson, and J. Sobel. Pre-symptomatic transmission of pandemic influenza
945 H1N1 2009: investigation of a family cluster, Brazil. *Epidemiol Infect*, 141:763–766, 2013. doi:
946 10.1017/S0950268812001501.

947 [53] J.C. Lopez-Marcos. An upwind scheme for a nonlinear hyperbolic integro-differential equa-
948 tion with integral boundary condition. *Comput Math Appl*, 22:15–28, 1991. doi: 10.1016/
949 0898-1221(91)90030-8.

950 [54] Monica Gandhi, Deborah S. Yokoe, and Diane V. Havlir. Asymptomatic transmission, the
951 Achilles heel of current strategies to control Covid-19. *N Engl J Med*, 382:2158–2160, 2020.
952 doi: 10.1056/NEJMe2009758.

953 [55] Luke Taylor. Covid-19: Hong Kong reports worlds highest death rate as zero covid strategy
954 fails. *BMJ*, page o707, 2022. doi: 10.1136/bmj.o707.